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A Introduction 
 
 
A.1 Structure and Function of Eukaryotic Chromatin 
 
The major function of DNA is to carry genes. DNA interacts with proteins that fold 
and pack the molecule into a compact structure in the nucleus. The genome of 
eukaryotes is structured in chromosomes, a dynamic complex of DNA and 
proteins. In addition to the proteins involved in packaging DNA, chromosomes 
are also associated with many proteins required for the processes of gene 
expression, DNA replication and DNA repair. The proteins binding to DNA to 
associate eukaryotic chromosomes are divided into two classes, the histone and 
the nonhistone chromosomal proteins. The compression administrated by both 
classes of proteins with DNA is called chromatin. Histones are present in high 
quantities so that their total mass is almost equal to the mass of DNA. 
Histones are responsible for the basic level of chromosome organization, the 
nucleosome. A nucleosome is built by a histone octamer, known as “nucleosome 
core”. Each individual nucleosome core consists of a complex of two molecules 
each of the histones H2A, H2B, H3 and H4 and the DNA molecule. 146 base 
pairs of DNA are wrapped around the histone octamer in 1.65 turns and in a left-
handed coil. The total chromatin is compactly packed in a 30 nm fiber, Figure 1 
(Albert et al., 2006). 
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Figure 1. Different levels of DNA and protein packing (Albert et al., 2006) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.2 Covalent Modifications of the Histone Tails 
 
The four basic histones are composed of an N- and C-terminal tail and a globular 
domain, responsible for the histone folding. The histone N-tails extend  from the 
DNA-histone core and are easily accessible for a variety of covalent post-
translational modifications (PTMs), which control many aspects of the chromatin 
structure (Scharf and Imhof, 2007). Histones are synthesized in the cytosol and 
then assembled in the nucleus. Some modifications of the tails occur after 
synthesis and before nucleosome assembly, others after the nucleosome has 
been assembled (Albert et al., 2006). 
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PTMs have several important consequences such as the regulation of the 
functional state of chromatin, the stability of the 30 nm chromatin fiber and the 
gene expression. The modified histone tails have the ability to affect specific 
proteins to a stretch of chromatin and in this way can either cause higher 
compaction of the chromatin or can facilitate access to the DNA (Scharf, 2009).  
The types of PTMs studied currently are acetylation of lysines, phosphorylation of 
serines and threonines, methylation of arginines and lysines, ubiquitylation and 
sumoylation of lysines and ADP-ribosylation of glutamic acid (Imhof, 2006). 
 
A.3 PTMs and Epigenetics 
 
Epigenetics refer to heritable variations in gene expression without sequence 
changes of the DNA (Imhof, 2006). They are stable and essential for the cell fate. 
Epigenetics are dependent on cell genotype, cell development and environment 
and allow cells to respond and adapt to environmental stimuli (Heintzman et al., 
2009). Epigenetic mechanisms regulate all biological processes, including 
genome reprogramming during early embryogenesis, cell differentiation and cell 
fate (Barros and Offenbacher, 2009, de Sario, 2009). Key epigenetic players are 
DNA methylation and histone post-translational modifications, which interplay 
with each other, with regulatory proteins and with non-coding RNAs, to remodel 
chromatin and to achieve nuclear compartimentalization (Delcuve et al., 2009). 
PTMs could act in a combinatorial manner and heritably alter gene expression 
without a change in the DNA sequence (Cedar and Bergman, 2009). Thus, this 
mechanism allows facilitation of epigenetic therapy for different diseases and 
cancer (Egger et al., 2004, Pogribny et al., 2007) and interventions to treat a 
variety of neurological and psychiatric conditions (Jiang et al, 2008). The 
importance of epigenetics in regulating immune and inflammatory responses has 
been studied as well (Wilson, 2008).  
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A.4 Histone Acetylation and Histone Deacetylation 
 
Acetylation of lysines within the histone tails has an important role in the 
transcription. The acetylated state of chromatin is regulated by two counterpart 
group of enzymes, the histone acetyl transferases (HATs) and the histone 
deacetylases (HDACs) (Cheung et al., 2000), (Figure 2).  
 
Figure 2. Histone acetylation catalyzed by HATs and deacetylation process 
regulated by HDACs (Scharf, 2007) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Currently, studies show that 11 positions of lysines are acetylated: at H4 the 
positions K8, 12 and 16, at H3 the positions K9, 14, 18, 23 and 27, at H2A K7 
and at H2B K11 and 16 (Scharf, 2009). 
Histone acetylation is a reversible modification of lysine residues within the amino 
terminal domains of core histone. The acetylation process is triggered by the 
transfer of an acetyl-group from acetyl-coenzyme A to the ε-amino group of the 
lysine residue catalyzed by HATs. The opposite process, by which the acetyl 
Introduction 
 
 5 
group is removed by HDACs, is histone deacetylation. Histone acetylation tends 
to destabilize histone-DNA interactions (Ropero et. al, 2007). Histone acetylation 
of promoter regions correlates with the transcriptional activity of corresponding 
genes; in general, high levels of histone acetylation, i.e. hyperacetylation, are 
observed at the promoters of transcribed genes, whereas hypoacetylation 
correlates with repression of gene expression (Egger et al., 2004). Indeed, many 
of the known transcriptional co-regulators possess either HAT or HDAC activities 
(Frew et al., 2009). The processes of acetylation and deacetylation are highly 
dynamic (Katan-Khaykovich and Struhl, 2008). 
The mechanism how other modifications, for example methylation or 
phosphorylation, interact with acetylation and other transcriptional factors is 
largely unknown. This research area is of a great importance for a better 
understanding how genes are differently regulated and how more specific gene 
manipulation might be achieved. 
 
A.5 Histone Deacetylases 
 
Knowledge about structure, function and tissue distribution of the classical HDAC 
family members is needed to understand the mechanism of gene regulation via 
HDAC activity. In humans, 18 HDAC enzymes have been identified and 
categorized. Generally, HDACs comprise a family of enzymes that can 
deacetylate histones but also transcription factors including p53, FOXO, NF-kB, 
Ku70, Hps90. Thereby, HDACs regulate gene expression and cell cycle 
progression (Kim et al., 2009, Lin et al., 2006, Meraner et al., 2008).  
In humans eleven histone deacetylases (HDACs) and seven sirtuins (SIRTs) 
have been identified and partly characterized until now. The HDACs are divided 
into four classes. Molecular masses of class I HDACs (HDAC1, HDAC2, HDAC3 
and HDAC8) range from 42-55 kDa. Class II HDACs are subdivided in class IIa 
with the representatives HDAC4, HDAC5, HDAC7 and HDAC9 and class IIb with 
HDAC6 and HDAC10. All class II enzymes have molecular masses between 120-
130 kDa. Furthermore, class I and II HDACs are zinc-dependent enzymes and 
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their tissue distribution changes during the development of an organism. Class I 
HDACs are mainly present in the nucleus, whereas class II HDACs shuttle 
between cytoplasm and nucleus. HDACs of class III, the sirtuins (SIRT 1-7) are 
NAD-dependent and do not have histone as their primary substrate. Very little 
information is available for HDACs of class IV, HDAC11 is the only representative 
enzyme of this group (De Ruijter et al., 2003, Gregoretti et al., 2004, Witt et al., 
2009). 
HDACs do not bind directly to DNA, they are recruited to multi-protein complexes 
associated with DNA which differ in their subunit composition. The activities of 
HDACs appear to be regulated in part by protein-protein interactions. In addition, 
HDACs are regulated by gene expression, subcellular localization and other 
PTMs (phosphorylation, sumoylation), as well as by processes as proteolysis and 
the availability of metabolic cofactors (Marks et al., 2009). 
The role of HDACs on the physiological function in normal tissues and in 
organism development has been studied by generating knock out mice. 
Phenotypes of class I (HDAC1, 2 or 3) knock out mice resulted in defects of 
embryonic stem cell proliferation and multiple cardiac defects and led to an early 
embryonic lethality (Bhaskara et al., 2008, Haberland et al., 2009, Witt et al., 
2009). Class II knock out mice developed defects in different tissues and organs, 
and the loss of HDAC7 leads to embryonic death as well. Thus, HDAC enzymes 
of class II have been shown to be essential for muscle differentiation and T-cell 
differentiation and apoptosis (Fischle et al., 2001, Wang et al., 2009). The studies 
confirmed that HDACs regulate the appropriate maturation of heart, smooth 
muscles, brain, kidney, liver, spleen and pancreas (Minucci and Pelicci, 2006, 
Haberland et al., 2009, Witt et al., 2009). 
Imbalances in histone acetylation and/or deacetylation are assumed to play a 
crucial role in many “Western diseases” such as cancer, inflammation (Barnes 
2006, Heo et al., 2009, Ito et al., 2002, Zhang et al., 2009) and viral infections 
(Senese at al., 2007, Zhang et al., 2009). A contribution of HDACs in 
cardiovascular diseases is under investigation (Granger et al. 2008, Haberland et 
al., 2009, Oka et al., 2009, Olson and Schneider, 2003, Urbich et al., 2009). 
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Lately, the influence of HDACs on different neural processes, namely memory 
enhancement, synaptic plasticity (Guan et al., 2009, Li and Richardson, 2009, 
Stefanko et al., 2009, Taniura et al., 2007) and Parkinson’s diseases (Jiang et al., 
2008) has been discussed. 
 
A.6 Histone Deacetylatase Inhibitors 
 
Recently, histone deacetylase inhibitors (HDACi) are the focus of tremendous 
interest as anti-cancer drugs (Frew et al., 2009, Ishihara et al., 2004, Lin et al., 
2006, Marks and Xu, 2009, Ocker and Schneider-Stock, 2007, Rosato et al. 
2003, Place et al., 2005), neuropsychiatric agents (Kumral et al, 2009, 
MacDonald et al., 2009) and immunomodulators (Bhat et al., 2008, Wang et al., 
2009).  
Generally, HDACi are known to be able to induce growth arrest, differentiation or 
apoptosis and autophagocytotic cell death of cancer cells in vitro and in vivo 
(Bolden et al., 2006, Condorelli et al., 2008, Dokmanovic and Marks, 2005, Frew 
et al., 2009, Ishdorj et al., 2008, Marks and Xu, 2009, Oh et al. 2008, Oka et al., 
2009, Ropero and Esteller, 2007, Smith and Workman, 2009).  
They are structurally diverse molecules with the ability to inhibit HDACs with 
varying efficiencies from nanomolar to micromolar range (Liu et al., 2006). By 
epigenetic chromatin remodeling they influence tumor growth by repression of 
angiogenesis or by increasing tumor cell immunogenicity (Liu et al., 2006, 
Ogbomo et al., 2007, Savickiene et al., 2006). In many clinical trials effects of 
several HDAC inhibitors in different cancers are studied (Akare et al., 2006, 
Bolden et al., 2006, Carew et al. 2008, Dashwood et al., 2006, Frew et al., 2009, 
Garber, 2007, Habold et al., 2008, Marks and Xu, 2009, Oka et al., 2009, 
Ogbomo et al., 2007).  
However, most of the known HDAC modulators exert a rather unselective impact 
on HDAC activity (Bhaskara et al., 2008). Some pan-inhibitors, either natural or 
synthetic compounds already applied in clinical trials against cancer, induced 
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different cardiac complications, which are major disadvantages for a frequent use 
in therapy.  
The majority of these HDACi are microbial metabolites: e.g. romidepsin or 
trichostatin A, antibiotics with anti-fungal effects, are of bacterial origin, whereas 
depudecin, trapoxin A and B have been isolated from fungi. Novel marine natural 
products such as largozole, apicidine, azumamides and psammaplin A have 
shown HDAC-inhibitory activity at nanomolar concentrations (Newkirk et al., 
2009).  
Until now, only few plant metabolites, which possess HDAC inhibitory effects, are 
known. Flavone and flavone derivatives from Feijoa sellowiana Bert. exerted 
ability to inhibit HDAC 1 activity (Bontempo et al., 2007). A sulfur compound from 
the roots of Pleuropterus ciliinervis Nakai is a potent HDACi, with an IC50 value of 
1.43 µM (Son et al., 2007). Investigations of the rhizomes of Zingiber zerumbet L. 
have brought a new insight into the anti-cancer efficacy of this plant. Two major 
sesquiterpenoids, 6-methoxy-2E,9E-humuladien-8-one and zerumbone, were 
tested in vitro for HDAC inhibition and IC50 values of 1.25 and 8.35 µM, 
respectively, were determined (Chung et al., 2008). A recent study of a 
methanolic extract of the stem of Microtropis japonica (Franchet & Savatier) has 
revealed the potential of triterpenoids and ursolic acid to inhibit HDAC activity at 
concentrations of 20 µg/ml as shown by the increase in the acetylated state of 
histone 3 (Chen et al., 2009).  
 
Further investigations on the specific functions of individual HDACs as well as the 
mechanism of action and the role of HDACi in normal cells are needed in order to 
ensure less adverse effects of HDACi in therapy. 
 
The challenge in the field is to develop new compounds, which are effective and 
have particular function on “disease” related HDACs. First examples of active 
plant compounds underline that in this search for selective HDAC modulators the 
almost infinite structural biodiversity of plant kingdom could provide new 
promising substances for further development. Natural products have been a 
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highly important source of leads for the development of drugs. The expectations 
are that a more efficient and effective search for natural products will lead to 
discovery of a successful drug (Harvey, 2008). To speed-up the isolation of 
respective candidates in a bioactivity-guided approach, a suitable test method is 
indispensable.  
 
A.7 HDAC Assay 
 
A fluorimetric in vitro enzyme assay has been developed for the investigation of 
the influence of pure compounds on the activity of class I and class II HDACs. 
The principle of the assay is based on the following reactions: an ε-acetylated 
lysine-based substrate C-terminally coupled with 4-methyl-coumarine-7-amide 
(MCA) is deacetylated by HDAC. The deacetylated substance is recognized as a 
substrate by endopeptidase which releases 7-amino 4-methylcoumarin (AMC). 
Free AMC, in contrast to acetylated MCA, is highly fluorescent and can be 
monitored (Ciossek et al., 2008, Hildmann et al., 2006, Mazitchek et al. 2008, 
Riester et al., 2007, Wegener et al., 2003). The HDAC assay reactions are 
presented in Figure 3, page 10. 
 
To the best of our knowledge, this method had not yet been tested nor been 
optimized and validated for the investigation of complex plant extracts and their 
ability to modulate HDACs. 
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Figure 3. Schematic overview of the HDAC assay reactions (Wegener et al., 
2003) 
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A.8 HDACs and Cardiovascular Diseases 
 
Patients with chronic heart failure develop cardiac hypertrophy under 
enlargement of the heart. Cardiac hypertrophy is the heart’s response to a variety 
of extrinsic and intrinsic stimuli that impose increased biomedical stress (Barry et 
al., 2008, Force, 2008). 
The causes and effects of cardiac hypertrophy have been precisely documented, 
although the molecular mechanisms, the responsible signals to cell changes, or 
cardiac signaling pathways are still poorly understood (Bradner, 2009). The 
modulation of myocardial growth was studied as a potential approach in the 
prevention and treatment of heart failure. Cardiac hypertrophy and heart failure 
are associated with activation of multiple pathways, confirmed by in vivo 
experiments (Force, 2008). 
 
Studies have shown that HATs and HDACs participate in the regulation of 
hypertrophic heart response (Frey and Olson, 2003, Kook et al., 2003). The 
results suggest a potential role of HDACi as a therapy to control cardiac 
hypertrophy (Kong et al., 2006, Olson et al., 2003, Wei at al., 2008). 
Nevertheless, further investigations in this area are needed. 
 
A.9 Leonuri Herba as Traditional Remedy against Heart 
Complaints 
 
Leonuri herba consists of whole or cut, dried flowering aerial parts of Leonurus 
cardiaca L. (Lamiaceae). Other common names for the plant are motherwort, 
lion’s ear, lion’s tail or throw-wort.  
The geographical areas of growth are western, eastern and central Asia, the 
plant is broadly distributed in central and eastern European regions, as well as in 
North Africa and North America. The plant prefers light (sandy), medium (loamy) 
and heavy (clay) soils and can grow under nutritionally poor condition, it requires 
moist and light (WHO, 2006). 
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The plant can grow to a height of up to 1.2 m. The stem is erect, quadrangular, 
grooved, hollow, pale green or purplish brown with usually hairy, opposite and 
decussate leaves. The leaves have serrated margins and are palmately lobed 
with long petioles, basal leaves are wedge shaped with three points while the 
upper leaves are more latticed. Flowers appear in leaf axils on the upper part. 
The 6 to 12 flowers are small, with green, bell shaped calyx with 5 equal pointed 
lobes, the corolla is 2-lipped pubescent, white with purplish spots on the furry 
lower lip. The fruit is a brown, triangular nutlet, 2.5 to 3 mm long with a tuft of hair 
at the tip, (WHO, 2006), Figure 4. 
 
Figure 4. Leonurus cardiaca L. 
 
 
 
 
 
 
 
 
 
 
 
 
 
http://caliban.mpiz-koeln.mpg.de/thome/band4/tafel_063_small.jpg 
 
Main constituents of Leonuri herba are flavonoids, at minimum 0.2%, mainly O-
glycosides of apigenin, kaempferol and quercetin. An overview of the 
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characterized constituents of Leonuri herba is presented in Table 1 (Melichar, 
2007). 
 
Table 1: Constituents of Leonuri herba 
Class compound 
Diterpenes leocardin, leosibricin 
Iridoides ajugoside, ajugol, galiridoside, reptoside 
Flavones rutin, quercitrin, isoquercitrin, hyperoside, genkwanin 
Alkaloids betonicine, stachydrine 
phenolic acids derivatives caffeic-acid-4-O-rutinoside, leonurin 
essential oil 0.001 – 0.002% 
Triterpenes ursolic acid, oleanolic acid 
 
Pharmacological studies on the cardiovascular effects of an ethanolic extract of 
Leonuri herba showed direct myocardial actions, inhibiting the effects of calcium 
chloride and stimulating alpha and beta adrenoceptors in the heart (Melichar, 
2007).  
 
A sedative effect of Leonuri herba was shown by a significantly prolonged 
sleeping time in mice (ESCOP, 2009).  
 
For ursolic acid, a terpenoid constituent of Leonuri herba anticancer properties 
and cytotoxic properties were described (Ikeda et al., 2006, Ma et al., 2005, Tian 
et al., 2006, Yim et al., 2006).  
 
In European traditional medicine Leonuri herba has been used for long against 
hearth complaints in order to strengthen the heart, as well as in nervous cardiac 
disorders (Melichar, 2007). 
 
Due to these facts, this drug was selected as an example for a bioactivity-guided 
fractionation and detailed study in the search of novel HDACi. 
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A.10 TCM Preparation against Cardiac Complaints 
 
A decoction of a preparation from traditional Chinese medicine (TCM) containing 
four different herbal drugs has been used in the treatment of cardiovascular 
diseases. This preparation has shown a significant increase in the survival rate of 
mice after experimental cardiac infarction (Ma, unpublished data). 
 
Thus, the effect of this decoction and its ingredients on HDAC activity was of 
interest. 
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B Aim of the Work 
 
 
Recently, histone deacetylase inhibitors (HDACi) have received high interest as 
anti-cancer agents. In many clinical trials effects of several HDACi on different 
tumors are studied at the moment. Plant kingdom provides an almost infinite 
structural biodiversity. Thus, the purpose of this work was the establishment and 
optimization of an in vitro HDAC assay for determination the enzyme activity of 
histone deacetylases.  
The optimization process should assure high efficacy and improvement of the 
experimental design to make the assay a powerful tool for primary screening of 
complex extracts and fractions from plant origin for modulators of HDAC activity. 
The influence of diverse factors on the enzyme activity such as temperature, pH 
range, buffer composition, incubation times and enzyme sources had to be 
investigated. The comparison between normal and cancer cells, human versus 
rodent cells and epithelial, endothelial or muscle cell can provide significant 
information for the application of the assay searching for new leads in defined 
diseases. 
The assay design should not only allow the use of nuclear extracts containing 
mixtures of HDACs but give insights on the influence of potent analytes on single 
HDACs as well. 
 
The influence of primary and secondary plant’s metabolites, which might 
negatively influence the assay due to autofluorescence interfering with the 
wavelength of emission or due to precipitation of the enzyme, had to be studied. 
After successful validation of the test system the application for bioactivity-guided 
searches should be studied on an example. For this purpose Leonuri herba was 
selected from the VOLKSMED database, in which knowledge of Austrian 
traditional medicine is comiled. Due to the fact that HDACs seem to be involved 
in cardiac complaints this drug seemed to be a good candidate to prove the 
applicability of the assay on extracts, fractions and purified compounds.  
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C Materials and Methods 
 
 
C.1 Plant Materials 
 
C.1.1 Components of a Herbal Mixture from TCM 
 
We received the single herbs (TCM 1 – TCM 4) from Dr. Y. Ma, Department of 
Pathophysiology, Medical University of Vienna.  
 
TCM 1  roots of Glycyrrhiza uralensis Fisch ex DC. 
TCM 2  rhizomes of Zingiber officinale Roscoe 
TCM 3  tubers of Aconitum carmichaeli Debx. 
TCM 4  cortex of Cinnamomum cassia Nees 
TCM 5  mixture of the single herbs 
 
C.1.2 Ratanhiae radix  
 
The root of Krameria triandra Domb. Burd et Simp. was obtained by Mag. pharm. 
R. Kottas-Heldenberg & Sohn Drogenhandel GmbH, Vienna, Austria (Ch. No.: 
KLA60374). 
 
C.1.3 Viburni cortex 
 
The bark of Viburnum opulus L. was obtained by Heinrich Klenk GmbH & Co. 
KG, Schwebheim, Germany (Ch. No.: 323213). 
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C.1.4 Leonuri herba 
 
The herb of Leonurus cardiaca L. was obtained by Mag. pharm. R. Kottas-
Heldenberg & Sohn Drogenhandel GmbH, Vienna, Austria (Ch. No.: KLA70811), 
the botanical identification was carried out by Ass. Prof. Dr. Christa Kletter, 
Department of Pharmacognosy, University of Vienna. 
 
C.2 Extraction and Fractionation 
 
C.2.1 Extraction of the TCM-mixture and its Components 
 
The herbs were powdered and 1.0 g was soaked in 10 ml water for 1 hour. Then, 
extraction under reflux at 100°C for 30 minutes fol lowed. The extracts were 
filtered. The clear aqueous solutions were lyophilized and yielded the amounts 
shown in Table 2. The lyophilized extracts of the single herbs (TCM 1- TCM 4) 
and of the mixture (TCM 5) were tested for their effect on HDAC activity. For that 
purpose each extract was dissolved in 20 µl DMSO and 980 µl assay buffer to 
final concentrations of 2 mg/ml.  
 
Table 2: Yields of TCM extracts 
TCM yield, mg per g drug 
TCM 1 93.65 
TCM 2 31.14 
TCM 3 123.23 
TCM 4 57.67 
TCM 5 112.54 
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C.2.2 Extraction of Ratanhiae radix and Detannification of the 
Extract 
 
2 g powdered plant material were extracted with 100 ml water under reflux for 30 
min. After filtration the extraction was repeated under the same conditions. The 
combined extracts were lyophilized, the yield was 299.3 mg. 10 mg of the dried 
extract were dissolved in 1 ml solvent (20 µl DMSO and 980 µl assay buffer). 
Concentrations between 0.20 to 1 mg/ml were tested in the HDAC assay.  
For detannification 50 mg lyophilized extract were dissolved in 500 µl MeOH. 
Partition between 2 ml water-methanol (1+9) and 2 ml hexane was performed. 
After separation the apolar phase was discarded, subsequently 2 ml chloroform 
were added to the aqueous phase and partitioned. The detannified chloroform 
phase and the aqueous phase were dried under reduced pressure at 40°C, 
yielding 7 mg and 28.5 mg, respectively. The detannified chloroform fraction was 
tested at concentrations from 2 to 10 mg/ml for their effect on HDAC activity. For 
this purpose 5 mg were dissolved in 125 µl solvent (5 µl DMSO and 120 µl assay 
buffer and further diluted). The aqueous fraction enriched in tannins was tested at 
concentrations from 0.2 to 1 mg/ml, here 4 mg were dissolved in 1 ml solvent (20 
µl DMSO and 980 µl assay buffer and further diluted). 
 
C.2.3 Extraction of Viburni cortex 
 
The dried plant material was milled and extracted in a solvent-series of 
increasing polarity with dichloromethane (CH2Cl2), ethyl acetate (EtOAc), 
methanol (MeOH) and water (H2O).  
8 g powdered plant material was extracted with 100 ml solvent under reflux for 30 
min. After filtration the extraction of the residue was repeated twice under the 
same conditions. This procedure was used for each of the solvents. The 
combined extracts were dried by evaporation under reduced pressure at 40°C 
and the yields were 146.2 mg (CH2Cl2), 216.3 mg (EtOAc), 731.2 mg (MeOH) 
and 766.2 mg (H2O), respectively. The dried residues were tested for their effect 
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on the HDAC activity. 10 mg of the dried extracts were dissolved in 250 µl 
solvent (5 µl DMSO and 245 µl assay buffer) and diluted to final concentrations of 
10 mg/ml in the assay.  
 
C.2.4 Extraction of Leonuri herba – Analytical Scale 
 
The dried plant material was milled and extracted in a solvent-series of 
increasing polarity with dichloromethane (CH2Cl2), ethyl acetate (EtOAc), 
methanol (MeOH) and water (H2O).  
9 g powdered plant material was extracted with 100 ml solvent under reflux for 30 
min. After filtration the extraction of the residue was repeated twice under the 
same conditions. This procedure was used for each of the solvents. The 
combined extracts were dried by evaporation under reduced pressure at 40°C 
and the yields were 190.1 mg (CH2Cl2), 98.3 mg (EtOAc), 759.4 mg (MeOH) and 
767.9 mg (H2O), respectively. The dried residues were tested for their effect on 
the HDAC activity. 10 mg of the dried extracts were dissolved in 250 µl solvent (5 
µl DMSO and 245 µl assay buffer) and diluted to final concentrations of 10 mg/ml 
in the assay.  
 
C.2.5 Extraction of Leonuri herba – Preparative Scale 
 
1.0 kg of the powdered dry plant material (in portions of 250.0 g) was extracted 
under reflux with 5.5 l methanol for 30 minutes. The supernatant was removed 
and filtered. The residue was extracted for another 30 minutes under reflux with 
5.5 l methanol. After filtration the combined extract solutions were evaporated 
under reduced pressure at 40°C and the yield was 93 .1 g.  
 
C.2.6 Removal of Chlorophyll from the Extract of Leonuri herba 
 
It is known that chlorophyll interferes unspecifically with numerous proteins. In 
order to exclude a false result, chlorophyll was removed from the extract. The 
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applied method was based on a liquid-liquid-partition of the extract between 
water and chloroform and subsequently water and ethyl acetate.  
The dried methanolic extract of Leonuri herba was dissolved in 500 ml water in 
an ultrasonic bath for 30 min at room temperature. The clear solution was 
partitioned twice with chloroform. The chloroform phases were removed and 
yielded 23.4 g after evaporation. The partition was further performed twice with 
ethyl acetate resulting in a yield of 1.7 g. The chlorophyll free aqueous extract 
was lyophilized. The yield was 67.8 g. All fractions were characterized by TLC 
and HPLC. The lyophilized chlorophyll-free extract was tested at a concentration 
of 10 mg/ml in the HDAC assay and bioactivity guided fractionation followed. 
 
In a preliminary test, 4 g of the purified extract were fractionated by Solid Phase 
Extraction (SPE) on C18-cartriges into five different fractions (see C.2.7). Due to 
high costs of this method, the major part of the extract (60.0 g) was separated by 
column chromatography on Sephadex LH 20 (see C.2.8, page 21). 
 
C.2.7 Solid Phase Extraction of the Purified Methanolic Extract from 
Leonuri herba 
 
A portion of 4 g of the methanolic extract obtained by exhaustive extraction 
(C.2.6, page 19) were dissolved in 4 ml 40% methanol in an ultrasonic bath for 
15 min at room temperature. Four cartridges (Varian Mega BE-C18; 5 g, 20 ml) 
were conditioned with two reservoir volumes (RV) methanol and two RV water. 1 
ml of the extract was applied on each of the four cartridges which were dried by 
air purge for 10 min. The extracts were eluted from each cartridge with 5 RV 
each of water (F1), 20% MeOH (F2), 40% MeOH (F3), 80% MeOH (F4) and 
100% MeOH (F5) at flow rates of 5 ml/min. The fractions of identical polarity were 
pooled. After removal of methanol from the obtained fractions by evaporation, the 
aqueous solutions were lyophilized. The yields were 2.70 g F1, 240 mg F2, 310 
mg F3, 54 mg F4 and 49 mg F5. 
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20 mg of the dried extracts were dissolved in 500 µl solvent (10 µl DMSO and 
490 ml assay buffer) and diluted to final concentrations of 1 mg/ml in the assay. 
The fractions were further analyzed and characterized by chromatographic 
methods. 
 
Fraction F3 was further separated by centrifugal partition chromatography (see 
C.3.1). 86.0 mg of F3 were solved in an ultrasonic bath in 2 ml ethyl acetate-
water (1:1) for 30 min. The sample fractionation was started at a flow of 1.5 
ml/min. 70 fractions with a volume of 10.5 ml were collected. Then methanol was 
pumped into the system at flow rate 9 ml/min. 23 methanol fractions at a volume 
of 18 ml were collected additionally. All fractions were evaporated and analyzed 
by TLC.  
 
C.2.8 Gel Permeation Chromatography of the Methanolic Extract of 
Leonuri herba 
 
The major part of the extract of Leonurus cardiaca L. (60.0 g) after chlorophyll 
removal (C.2.6, page 19) was separated by column chromatography on 
Sephadex LH 20 with water – methanol as a mobile phase (C.3.2, page 22). 
Each fifth fraction was analyzed by TLC.  
 
C.3 Chromatographic Methods 
 
C.3.1 Centrifugal Partition Chromatography (CPC) 
 
Instrumentation: 
High Speed Countercurrent Chromatograph CCC 100, Pharma Tech Research, 
Baltimore, USA  
Mode of operation  tail to head  
Stationary phase   water 
Mobile phase    ethyl acetate 
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Distribution coefficient of F3 0.75 
Flow rate   1.5 ml/min 
Fraction size   15 ml 
 
C.3.2 Column Chromatography on Sephadex LH-20 
 
Column length   80 cm 
Column diameter  3 cm 
Stationary phase   Sephadex LH-20 
Mobile phase    water (fraction 1 to 100) 
    20% methanol (fraction 101 to 200) 
    40% methanol (fraction 201 to 300) 
    80% methanol (fraction 301 to 400) 
    100% methanol (fraction to 401 to 500) 
Amount of loading sample  60 g in two portions (31 g and 29 g)  
Flow rate   40 ml/h 
Fraction size   20 ml 
 
C.3.3 Thin Layer Chromatography (TLC) 
 
Thin Layer Chromatography was used for the characterization of the fractions. 
 
System 1 
Stationary phase   TLC plates 20 x 20 cm silica gel 60 F254; Merck, 
Darmstadt, Germany 
Mobile phase   ethyl acetate – formic acid – acetic acid – water 
(100+11+11+26) 
System 2 
Stationary phase   Cellulose F plates 20 x 20 cm, 250µ F254; Merck, 
Darmstadt, Germany 
Mobile phase   30% acetic acid 
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System 3 
Stationary phase   Polygram 20 x 20 cm polyamide plates 6 UV254; MN, 
Düren, Germany 
Mobile phase   toluene - petrol ether - butanone – methanol 
(18.5+4.5+9+6) 
Detection: 
The plates were sprayed with  
• NEU reagent: 1% methanolic diphenylboryloxyethylamine 
solution, followed by 5% ethanolic solution of polyethylene glycol 400 
(PEG-400). Detection was performed under UV 365 nm (Wagner and 
Bladt, 1996).  
• Anisaldehyde sulfuric acid reagent: mixture of 10 ml acetic acid, 
85 ml methanol, 5 ml concentrated sulfuric acid and 0.5 ml 
anisaldehyde. Detection at day light followed heating at 105°C for 5 to 
10 minutes (Wagner and Bladt, 1996). 
 
Sample Preparation for TLC 
5.0 – 10.0 mg samples were dissolved in 1 ml methanol and 10 - 20 µl were 
applied for analysis. 
 
C.3.4 High Performance Liquid Chromatography (HPLC) 
 
Instrumentation: 
Degasser  Shimadzu DGU 20A5 prominence Degasser 
Controller  Shimadzu CBM 20A prominence Communication Bus 
Module 
Autosampler  Shimadzu SIL 20AC HT prominence Auto Sampler 
Pump   Shimadzu LC 20AD prominence Liquid Chromatograph 
Detector  Shimadzu SPD M20A prominence Diode Array Detector 
Column oven  Shimadzu CTO 20AC prominence Column Oven 
Software  LC Solution 
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System 1 
Column  Hypersil BDS C18, 250 mm x 4 mm; 5µm Agilent, St. 
Clara, US 
Eluent A  water adjusted to pH 2.8 with acetic acid 
Eluent B  acetonitrile (acidified with appr. 3 ml/L conc. acetic acid)  
Composition at the beginning of analysis 85% A + 15% B. 
Flow rate  1 ml/min  
Temperature  30 °C 
 
Table 3: Gradient program 1 
time, min % eluent B 
0.0 – 1.0 15 
1.0 – 15.0 50 
15.0 – 30.0 60 
30.0 – 40.0 80 
40.0 – 50.0 100 
 
System 2 
Column  ACE C18-AR, 150 mm x 2.1 mm; 3µm, ACE Aberdeen, 
Scotland 
Eluent A  water adjusted to pH 2.8 with acetic acid 
Eluent B  acetonitrile (acidified with appr. 3 ml/L conc. acetic acid) 
Composition at the beginning of analysis 88% A + 12% B. 
Flow rate  0.35 ml/min 
Temperature  35 °C 
 
Table 4: Gradient program 2 
time, min % eluent B 
0. 0 – 17.0 20.5 
17.0 – 30.0 43.9 
31.0 – 36.0 100.0 
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System 3  
Column  ACE C18-AR, 150 mm x 2.1 mm; 3µm, ACE, Aberdeen, 
Scotland 
Eluent A  water 
Eluent B  methanol 
Composition at the beginning of analysis 75% A + 25% B. 
Flow rate  0.35 ml/min 
Temperature  35 °C 
 
Table 5: Gradient program 3 
time, min % eluent B 
0.0 – 17.0 60 
17.0 – 22.0 100 
 
Sample Preparation for HPLC 
Samples were dissolved in methanol at a concentration of 1 mg/ml and 
centrifuged at 13’000 rpm for 10 min before injection into the HPLC system. 3 µl 
(System 2 and 3) or 10 µl (System 1) of the supernatant were used for HPLC-
analyses. 
 
C.3.5 Preparative HPLC 
 
Instrumentation: 
Controller  Shimadzu CBM 20A prominence Communication Bus 
Module 
Auto sampler  Shimadzu SIL 10AP Auto Sampler 
Pump   2 x Shimadzu LC 8A preparative Liquid Chromatograph 
Detector  Shimadzu SPD M20A prominence Diode Array Detector 
Fraction collector: Shimadzu FRC10 fraction collector 
Software  LC Solution 
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Column  MN Nucleosil 100-7 C18, 30 cm x 3 cm; 7µm, Macherey 
and Nagel, Düren, Germany 
Eluent A  water 
Eluent B  methanol 
Composition at the beginning of analysis 60% A + 40% B. 
Flow rate  30 ml/min 
Temperature  RT 
 
Table 6: Gradient program 4 
time, min % eluent B 
0.0 – 10.0 40 
10.0 – 20.0 95 
 
Sample Preparation 
Samples were dissolved in 40% methanol at a concentration of 100 mg/ml and 
250 µl were applied in each run.  
 
C.3.6 HPLC/LC-MSn analysis 
 
The LC-MS analyses were performed on an UltiMate 3000 Rapid Separation LC 
System (Dionex, Germering, Germany), coupled to a 3D quadrupole ion trap 
instrument equipped with an orthogonal ESI source (HCT, Bruker Daltonics, 
Bremen, Germany). The gradient program used for the analysis is summarized in 
Table 7, page 27. 
 
Instrumentation: 
Controller  Ultimate 3000 Dionex  
Autosampler  Ultimate 3000 RS Dionex Autosampler 
Pump   Ultimate 3000 RS Dionex Pump 
Detector  Ultimate 3000 RS Dionex Diode Array Detector 
   190 – 400 nm 
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Column oven  Ultimate 3000 RS Dionex Column Compartment 
Column  ACE C18-AR, 150 mm x 2.1 mm; 3 µm, ACE, Aberdeen, 
Scotland 
Software  Chromelion Xpress 
Eluent A  water 
Eluent B  methanol 
Composition at the beginning of analysis 70% A + 30% B. 
Flow rate:  0.35 ml/min 
Temperature:  35 °C 
 
Table 7: Gradient program for LC-MSn analysis 
time, min % eluent B 
0.0 – 10.0 30 
10.0 – 17.0 60 
17.0 – 20.0 80 
21.0 – 26.0 100 
 
The ESI ion source parameters were as follows: capillary voltage: 4.0 kV, 
nebulizer: 20 psi (N2), dry gas flow: 7 L/min (N2), and dry temperature: 330 °C. 
The mass spectrometer was operated in an automated data-dependent 
acquisition (DDA) mode where each negative ion MS scan (m/z 100-1500, 
average of 5 spectra) was followed by MS2 scans (m/z 40-1000, average of 5 
spectra, isolation window of 4 Th, fragmentation amplitude of 0.7 V) of the two 
most intense precursor ions and MS3 scans (m/z 40-1000, average of 5 spectra, 
isolation window of 4 Th, fragmentation amplitude of 0.7 V) of the most intense 
fragment ion in each MS2 scan. Helium was used as collision gas. 
 
Sample Preparation for HPLC/LC-MSn 
Samples were dissolved in methanol at a concentration of 1 mg/ml and 
centrifuged at 13’000 rpm for 10 min before injection into the HPLC system. 1 µl 
of the supernatant was used for HPLC/ LC-MSn analysis. 
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C.4 Cell Culture 
 
C.4.1 Cell Lines and Cultivation 
 
Primary rat vascular smooth muscle cells (VSMCs, kindly provided by Dr. A. 
Schwaiberger, University of Vienna) as well as HeLa cells (kindly provided by 
a.o. Prof. Dr. G. Krupitza, Medical University of Vienna) were cultured in 
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf 
serum, penicillin (1000 U/l) and streptomycin (1 mg/l) (all from LONZA, Belgium) 
and incubated at 37°C under an atmosphere of 5% CO 2 in air. 
Human umbilical vein endothelial cells (HUVECs, kindly provided by Dr. Y. 
Schilder, University of Vienna) were cultivated in endothelial basal medium 
(EBM) supplemented with 10% fetal calf serum, penicillin (1000 U/l), 
streptomycin (1 mg/l) and additives provided by the manufacturer (LONZA, 
Belgium) and incubated at 37°C under an atmosphere of 5% CO2 in air. 
 
C.4.2 Cell Storage, Freezing and Thawing 
 
Cells were harvested for storage at 100% confluence. They were trypsinized and 
centrifuged (1’100 rpm, 10 min, 4°C), the supernata nt was removed. Fresh 
medium was used to suspend the cells and 10% DMSO was added for 
cryoprotection. Aliquots of 1 ml containing approximately 106 cells were frozen at 
-80°C in cryovials. After storage in a double walle d Styrofoam box for several 
days they were transferred to liquid nitrogen at -196°C for long time storage. 
When the cells were thawed, they were suspended into 15 ml growth medium, 
the solution was centrifuged (1’100 rpm, 5 min, 4°C ) to remove any DMSO and 
the cells were suspended in fresh medium for further use. 
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C.4.3 Cell Viability 
 
Cell cultures were observed under microscope to study any morphological 
changes when incubated with and without tested compounds as well as to 
examine for any microbial contaminations.  
Additionally, a cell counter was used to quantify the cell viability. 500 µl cells in 
incubation medium were placed in a vial. A Vicell XR cell viability analyzer, 
Beckman Coulter, automatically added 500 µl trypan blue dye to the vial and the 
cell number and the cell viability were determined according to the supplier’s 
protocol by 50 measurements. 
 
C.5 Cell Based Assays 
 
C.5.1 In vitro Cytotoxicity Assay 
 
Resazurin was used to measure the metabolic activity of living cells. Viable cells 
continuously convert non-fluorescent resazurin to fluorescent resofurin, 
increasing the overall fluorescence and color of the medium. By measurement of 
fluorescence the cell viability was quantified. 
 
HeLa cells were grown overnight in transparent 96 well plates (Greiner, 
Frickenhausen, Germany) at concentrations of 2 x 104 cells per well in 200 µl 
DMEM medium. The medium was removed and the cells were washed with PBS 
buffer. Then, the cells were incubated for 24 hours with starvation medium 
containing 1% C-source. After 24 hours the medium was discarded, the cells 
were washed with PBS buffer and 180 µl of fresh DMEM medium containing 10% 
C-source were added. The tested compounds were solved in DMEM medium at 
concentrations between 100 to 1000 µM and 20 µl of the solutions were added to 
the wells. The end concentration of the tested compounds was 10 to 100 µM, 
respectively. The incubation period was 48 and 72 hours, respectively.  
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For the resazurin assay, 40 µl resazurin solution (0.1 mg/ml) was added to each 
well. The incubation time was 4 hours at 37°C. The fluorimetric measurement 
was performed at 535 nm excitation and 590 nm emission in a TECAN Genious 
microtiter plate reader. Appropriate blanks (dye without cells) were subtracted 
from the values. All measurements were performed in duplicate. 
 
C.5.2 Proliferation Assay 
 
Generally, intact DNA incorporates the crystal violet dye. The intensity of the 
absorbance is in correlation with the cell proliferation rate.  
 
Crystal Violet Staining 
For staining with crystal violet the HeLa cells were grown and incubated with the 
tested compounds as described (C.5.1, page 29). After complete removal of the 
medium, 100 µl of crystal violet solution (0.5% crystal violet in 20% MeOH) were 
added to the wells. The incubation time was 15 min at RT. Then the 96 well plate 
was washed with distilled water and completely dried overnight at RT. By addition 
of 200 µl solution of 0.1 M sodium citrate in ethanol the reaction was started. The 
plate was shaken for 10 min at RT, and the absorbance was measured at 550 
nm in a TECAN Sunrise microtiter plate reader. All measurements were 
performed in triplicate and appropriate blanks were subtracted from the values. 
 
C.6 Western Blot Analyses and Gel Electrophoresis 
 
C.6.1 Western Blot Analyses 
 
Western blot analyses were performed to determine the acetylated state of 
histones (AcH3 and AcH4) and acetylated tubulin after treatment with potential 
HDACm as well as to study their influence on cell cycle progression by the 
investigation of the expression of protein p21. For p21 and tubulin a gel gradient 
10% and for AcH3 and AcH4 a gel gradient 12% was used. 
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C.6.2 Gel Electrophoresis 
 
Stock solutions used for gel preparation: 
1.5 M Tris- Base pH 8.8 (Tris- Base 18.17 g/l, pH adjusted to 8.8 with HCl) 
1.25 M Tris- Base pH 6.8 (Tris- Base 15.14 g/l pH adjusted to 6.8 with HCl) 
SDS 10%  
APS 10%  
 
A total volume of 7.5 ml solution for the separating gel according to the 
composition given in Table 8 was placed in gel casters for polymerization. Next, a 
thin layer of isopropanol was added to assure gel homogeneity and to prevent air 
bubbles during polymerization.  
 
Table 8: Components used for the preparation of the separating gels 
solutions 10% gel gradient 12% gel gradient 
30% PAA 2.5 ml 3.0 ml 
1.5M Tris HCL 8.8 1.8 ml 1.8 ml 
10% SDS 75.0 µl 75.0 µl 
distilled water 3.0 ml 3.0 ml 
TEMED 7.5 µl 7.5 µl 
10% APS 37.5 µl 37.5 µl 
total 7.5 ml 7.5 ml 
 
The solution for the loading gel was prepared according to Table 9, page 32. 
After the solution was poured, a comb was placed to create wells for the 
samples.  
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Table 9: Components for the preparation of the loading gel 
solutions volume 
30% PAA  0.6 ml 
1.25M Tris HCL 6.8 37.5 µl 
10% SDS 37.5 µl 
distilled water 2.6 ml 
TEMED 7.5 µl 
10% APS 37.5 µl 
total 3.3 ml 
 
C.6.3 Protein Determination 
 
The amount of protein was quantified by the method of Bradford (Bradford, 
1976). The assay is based on the shift of the absorbance maximum for an acidic 
solution of Coomassie Brilliant Blue from 465 nm to 595 nm due to the binding to 
protein. Both hydrophobic and ionic interactions stabilize the anionic form of the 
dye causing a visible color change.  
 
The reaction was started by mixing 10 µl of appropriately diluted sample 
solutions with 190 µl of Bradford solution (1:5 dilution in water, Roti® - Quant, 
Roth, Germany) in a transparent 96 well plate (Greiner, Frickenhausen, 
Germany) at room temperature. The samples were shaken for 15 min on a 
laboratory shaker and then the extinction was measured at 595 nm in a TECAN 
Sunrise microtiter plate reader. The standard curve was prepared using bovine 
serum albumin (BSA) at concentrations between 0 and 20 µg. All measurements 
were performed in triplicate and appropriate blanks were subtracted from the 
values. 
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C.6.4 SDS Electrophoresis and Western Blot 
 
Buffers 
Epho-buffer (3.0 g Tris-Base, 14.4 g glycine and 1 g SDS in 1 l water) 
Blotting-buffer (15.2 g Tris-Base and 72.9 g glycine in 1 l water) 
TBS-T (3.0 g Tris-Base, 11.1 g sodium chloride, and 1 ml of Tween 20 in 1 l 
water at pH adjusted to 8.0 with HCl) 
ECL buffer (1 M Tris- Base pH 8.5) 
p-coumaric acid (0.15 g in 10 ml DMSO) 
luminol solution (0.44 g in 10 ml DMSO) 
Detection buffer: 1 ml ECL buffer, 22 µl p-coumaric acid solution, 50 µl luminol 
solution and 3 µl 30% hydrogen peroxide were mixed and replenished to 10 ml 
with water. 
 
30 - 40 µl samples with 20 µg proteins were mixed with 10 - 15 µl sample buffer 
(255 µl 10% SDS and 45 µl mercaptoethanol) and boiled at 95°C for five minutes. 
The pretreated samples and 5 µl native protein marker (Biorad, 20 - 250 kDA) 
were loaded into the wells of the gel. The gel was placed into the module tank, 
which was filled with epho-buffer. The gel was run for 1 hour at 30 mA.  
The membrane was preconditioned by soaking in methanol to transparency, then 
was transferred into a mixture of 100 ml blotting-buffer with 200 ml methanol and 
700 ml with water. After that the membrane was placed into the “sandwich” 
chamber with 2 fiber pads and 2 filter papers (all soaked in a blotting buffer).  
The blot was run at room temperature with blotting buffer. Running time was 90 
minutes at 100 V. After the trans-blot block, the membrane was incubated with 
5% nonfat dry milk in TBS-T for 1 hour, on a laboratory shaker at room 
temperature. The membrane was washed three times with TBS-T buffer for 10 
min at RT on a laboratory shaker. Incubation with a primary antibody was 
performed for 1 hour at RT (Table 10, page 34). The membrane was washed with 
TBS-T buffer three times for 10 min on a laboratory shaker. A secondary 
antibody was placed in 5% BSA solved in TBS-T or TBS-T only for 1 hour at RT 
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(Table 11). Finally, the membrane was three times washed with TBS-T and 
incubated with the detection buffer for 1 minute.  
Protein detection was performed with a LAS-3000TM luminescent image analyzer 
and quantification of bands with AIDATM software. 
 
Table 10: Used primary antibodies 
Target Source Dilution Provider 
Ac-H3 (lys9/lys 14) rabbit 1:1000 
in 5% BSA, TBS-T 
Cell Signaling Technology Inc. 
(Danvers, MA, USA) 
Ac-H4 (lys12) rabbit 1:1000 
in 5% BSA, TBS-T 
Cell Signaling Technology Inc. 
(Danvers, MA, USA) 
p21 rabbit 1:1000 
in TBS-T 
New England Biolabs 
(Beverly, MA, USA) 
Ac-tubulin mouse 1:1000 
in TBS-T 
Santa Cruz  
(Santa Cruz, CA, USA) 
α-tubulin mouse 1:1000 
in TBS-T 
Santa Cruz  
(Santa Cruz, CA, USA) 
 
Table 11: Used secondary antibodies, HRP linked antibodies 
Target Source Dilution Provider 
rabbit IgG  goat 1:2500  
in 5% BSA, TBS-T 
New England Biolabs 
(Beverly, MA, USA)  
mouse IgG goat 1:2500  
In TBS-T 
Upstate  
(Charlottesville, VA, USA) 
 
C.7 Preparation of Nuclear Extracts 
 
Buffers 
Buffer A (10 mM HEPES, 0.1 mM EDTA, 10 mM KCl, 1 mM DTT, 0.5 mM PMSF 
pH adjusted to 7.5 with HCl and replenished to 1 l with water) 
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Buffer B (20 mM HEPES, 1 mM EDTA, 420 mM NaCl, 1 mM DTT, 0.5 mM 
PMSF, pH adjusted to 7.0 with HCl and replenished to 1 l with water) 
 
Cells were grown in 100 mm dishes and harvested on ice by washing them twice 
with phosphate buffered saline (PBS) and scraping the cells into 1 ml of PBS. 
The cells were transferred to pre-cooled Eppendorf tubes and centrifuged 
(13’000 rpm, 10 min, 4°C), the supernatant was disc arded. The pellet was 
incubated with 100 µl of buffer A  for 15 min at 4°C on a laboratory shaker, 
centrifuged (13’000 rpm, 2 min, 4°C) and the supern atant, which contained 
cytosolic proteins, was removed. The pellet was further incubated with buffer B 
for 15 min at 4°C on a laboratory shaker and centri fuged (13’000 rpm, 5 min, 
4°C) to precipitate DNA. The supernatant comprising  the nuclear extract was 
used as source of HDAC proteins. Aliquots of 100 µl were stored at -80°C. 
Protein content was determined by the Bradford method. 
 
C.8 Immunoprecipitation (IP) with A-Sepharose Beads 
 
The protocol used for isolation of HDAC 5 was based on the application of 
protein A coupled to an insoluble A-sepharose resin. An antibody-HDAC 5 was 
used to capture HDAC 5 from the nuclear extract. Then, in the solution the 
antigen-antibody complex was built and bound to protein A on the A-sepharose 
resin. By centrifugation the complex was precipitated and separated from the 
lysate proteins. The complex was further characterized. 
 
Sample Preparation 
2 ml of nuclear extract, with a protein content of 1 µg/ml, was mixed with 2 ml 
affinity pure antibody-HDAC 5 (Sigma, H9663, 1 µg/ml protein). The incubation 
was performed overnight at 4°C. Then, 100 µl A-seph arose beads were added 
and the mixture was further incubated on a rotating device for 2 hours at 4°C. 
The mixture was centrifuged at 7’000 rpm for 10 minutes at 4°C. The beads were 
twice washed with PBS buffer. The beads were incubated with 100 µl lyses buffer 
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on a rotating device for 30 minutes at 4°C, and the n again centrifuged at 7’000 
rpm for 10 minutes at 4°C. The supernatant was used  for further characterization 
in the HDAC assay. The beads were mixed with SDS buffer for Western blot 
analysis. 
 
C.9 HDAC Assay 
 
The assay was carried out in black 386-well plates (Greiner, Frickenhausen, 
Germany).  
As a blank 10 µl assay buffer (25 mM Tris-HCl pH 8.0, 137 mM NaCl, 2.7 mM 
KCl, 1 mM MgCl2) were mixed with 50 µM assay substrate (10 µl), an ε-
acetylated lysine-based substrate C-terminally coupled with 4-methyl-coumarine-
7-amide.  
As a control (i.e. 100 % HDAC activity) 5 µl assay buffer were incubated with 5 µl 
of the enzyme source (40 µg/ml nuclear proteins) and 10 µl assay substrate.  
TSA as a characterized HDAC inhibitor served as a positive control. Here, the 
assay buffer (5 µl) contained 4 µM TSA, the enzyme source (5 µl) and the assay 
substrate (10 µl).  
The samples were prepared by addition of 5 µl of the assay buffer, containing 
different concentrations of the tested compounds (200 µM to 1 mM), with 5 µl of 
the enzyme source and 10 µl of the assay substrate.  
By subsequent addition of 10 µl activator solution (solution of endopeptidase in 
presence of 1 µM TSA) the deacetylation reaction was stopped and the 
fluorophore was selectively released from the deacetylated substrate. The 
fluorophore was excitated at 360 nm and its emission was measured at 465 nm 
in a TECAN Genios microtiter plate reader. All measurements were performed in 
duplicate. The activity of the enzyme was expressed in relative fluorescence units 
(RFU). 
 
RFU = [(RFU enzyme–RFU blank)/slope*reaction time]*(V enzyme+V substrate)/V enzyme] 
V- volume, µl 
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Control HeLa nuclear extract was purchased from Upstate (12-309) and used for 
the comparison of the activity of self-isolated nuclear extracts from VSMC, 
HUVECs and HeLa cells prepared according to the C.7, page 34. 
 
For the study of natural compounds, extracts and fractions generally, all samples 
were primarily dissolved in dimethyl sulfoxide and further diluted with the assay 
buffer in ratio 1:50 prior to the application in the assay to obtain an end 
concentration of maximal 1% DMSO. Concentrations of 200 µM to 1 mM for pure 
compounds and of 1 mg/ml to 10 mg/ml for extracts and fractions were studied. 
IC50 values of some HDAC modulators were determined by fitting a sigmoidal 
dose response curve with variable slope (GraphPad Prism). 
 
C.10 Cell Imaging 
 
C.10.1 Preparation of Poly-L-Lysine (PLL) Coated Cover Slips  
 
Glass cover slips (12 mm) were heated with 1M HCl at 50 - 60°C overnight. Then 
they were cooled to room temperature. Three washing steps were performed for 
30 min each, on a laboratory shaker. The cover slips were incubated overnight 
with 15 ml PLL solution (1 mg/ml in distilled water) in a Petri dish on a laboratory 
shaker at 4°C. Due to toxicity of free polyaminoaci ds the cover slips had to be 
precisely washed ten times with distilled water. They were dried on a filter paper 
and stored in a sterile Petri dish. Before use, the cover slips were rinsed in 100% 
EtOH at sterile conditions and dried properly for cell cultivation. 
 
C.10.2 Cell Preparation for Imaging 
 
HeLa cells were cultured overnight on the pretreated PLL coverslips at 
concentrations of 2 x 104 cells/ml in 6 well plates (Greiner, Frickenhausen, 
Germany).  
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HeLa cells were incubated with the active compounds or extracts for 24 and 48 
hours. Studies of the cytoskeletal phenotypes were performed after treatment of 
the HeLa cells with the extract or fractions at three different concentrations (20.0, 
30.0, 40.0 µg per 1 ml DMSO) whereas for the pure compounds (aloin, rutin, 
sennoside A and B, verbascoside and stachydrine) concentrations of 25, 37.5 
and 50 µM were used.  
The cells were fixed and double immunofluorescent labeled according to an 
optimized protocol of Mitchison group (http://mitchison.med.harvard.edu).  
 
Buffers 
CB stock buffer (40 mM MES pH 6.1, 452 mM KCl, 12 mM MgCl2 and 8 mM 
EGTA in 100 ml water) 
CBS buffer (500 µl 16% formaldehyde solution, 500 µl CB stock buffer and 500 µl 
of 1.28 mM sucrose in 2 ml water) 
Abdil buffer (TBS-0.1% TX, 2% BSA, and 0.1% azide in 100 ml water) 
 
Sample Preparation 
After incubation of HeLa cells with tested compounds for 24 or 48 hours, the 
DMEM medium was removed and the cells were fixed with 4% formaldehyde 
solution in CBS buffer for 20 minutes. Then the cells were rinsed with TBS buffer, 
3 changes in 5 minutes were adequate. The cells were permeabilized with TBS-
0.5% TX buffer for 10 minutes and again rinsed three times with TBS-0.1% TX 
buffer, 3 changes in 5 minutes were adequate. By addition of Abdil buffer the 
cells were blocked for 10 minutes, then the incubation with 1 µg/ml fluorescent 
phalloidin in Abdil buffer followed for 20 minutes at RT. 
 
The tubulin cytoskeleton in fixed cells was observed by use of TRITC-conjugated 
rhodamine. After incubation of the HeLa cells the medium was removed and the 
cells were fixed and treated as described above, then the incubation with 
fluorescent rhodamine (1:500 in Abdil buffer) followed for 60 minutes at RT. 
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5 µg/ml Hoechst in Abdil buffer was used to stain the nuclei by incubation of the 
cells for 10 minutes at RT.  
 
Finally, the cover slips were washed with TBS-0.1%TX and three times rinsed 
with TBS. The rest of TBS buffer was drained, and the cover slips rapidly dried 
under air stream, mounted and sealed on preparative glass covers. Mounting 
medium was 0.5% p-phenylenediamine (Sigma 87890) in 20 mM Tris, pH 8.8, 
90% glycerol. The preparative glasses were stored in dark and cold (-80°C) 
conditions. Observations were performed by using a fluorescence microscope 
Olympus BX51, (Olympus Europe GmbH, Hamburg, Germany). The analysis 
parameters were FITC 900ms (actin), TRITC 6s (tubulin), and Dapi 200ms (DNA) 
after incubation of the cells for 24 hours. In contrary the experiments with 48 
hours of incubation were studied by adjusting the analysis parameters as follows: 
FITC 600ms, TRITC 2s, and Dapi 90ms.  
 
C.11 Other Technical Equipment and Software 
 
Cell viability analyzer and cell counter Vi-Cell TM XR (Beckman Coulter, Fullerton, 
CA, USA) 
TECAN Sunrise TM microplate reader (TECAN, Mannedorf, Switzerland)  
TECAN GENios Pro TM microplate reader (TECAN, Mannedorf, Switzerland) 
Fluorescence microscope Olympus BX51 (Olympus Europe GmbH, Hamburg, 
Germany) 
Analyzing software: cell^F software (Europe GmbH, Hamburg, Germany) 
Light microscope Olympus CKX31 (Olympus Europe GmbH, Hamburg, 
Germany) 
Camera: Olympus Live View Digital SLR Camera E-330 (Olympus Europe 
GmbH, Hamburg, Germany) 
 Analyzing software: Cellprofiler software (www.cellprofiler.org) 
Luminescence image analyzer LAS-3000TM (Fujifilm Global, Tokyo, Japan) 
Analyzing software: AIDATM (Fujifilm Global, Tokyo, Japan) 
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C.12 Statistics 
 
The statistical analyses were performed using GraphPad PRISM TM, version 4.03 
(GraphPad Software Inc, San Diego, CA, USA). Data are expressed as means of 
at least three independent experiments including standard deviation or standard 
error.  
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D Results 
 
 
D.1 Assay Validation and Optimization 
 
Various parameters had to be determined in order to apply the fluorimetric assay 
for the study of the effects of complex plant extracts and mixtures on HDAC 
activity. 
The assay optimization included detailed investigation of several factors, e.g. 
temperature, incubation times, the role of pH and cations and anions, the intra- 
and interday reproducibility, the applicability of different enzyme sources and 
HDAC substrate, as well appropriate positive control and influence of fluorescent 
compounds. The results obtained in the optimization process added important 
knowledge for the application of the HDAC assay as suitable tool for the in vitro 
search of HDAC modulators from plant origin. 
 
D.1.1 Linearity 
 
A linear standard curve of AMC was required for the reliable determination of the 
activity of the HDAC source and its modulation by the tested compounds. 
Optimal sensitivity for detection of AMC fluorescence was obtained at 360 nm 
excitation and 465 nm emission. The intensity of released fluorophore was 
measured after incubation of the test mixture and the activator solution. A 
standard curve using different concentrations of unacetylated AMC (0 - 20 µM) 
displayed excellent linear correlation (r2 = 0.9975) between AMC concentration 
and the relative fluorescence units after correction for the appropriate blanks 
Figure 5, page 42. 
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Figure 5. Standard curve of AMC at concentrations between 0 and 20 µM 
 
 
 
 
 
 
 
 
 
 
 
 
D.1.2 Source of HDAC 
 
Three different well-established cell types were used for the preparation of the 
nuclear protein, namely HUVECs, HeLa and VSMCs. By selecting these cell 
types, normal human cells (HUVECs) were compared with cancer cells (HeLa) 
and rodent cells (rat VSMCs). The use of different HDAC sources was used to 
study different implications of the HDACs in different cell types, for example in 
epithelial (HeLa), endothelial (HUVECs) and smooth muscle cells (VSMCs). 
 
It has been proven that the total amount of HDACs is almost equally expressed in 
normal and in tumor cells, the HDACs content is differently distributed in various 
cell types (De Ruijter et al., 2003). By comparison of the HDAC activity in nuclear 
extracts of HeLa, HUVEC and VSMC cells a similar level was observed (Figure 
6, page 43). 
 
The activity of the enzyme was expressed in units, with one unit (U) 
corresponding to 1 µM deacetylated product released per minute at RT.  
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Based on the quantification of the protein content in correlation to the HDAC 
activity a specific HDAC activity of approximately 2 U/mg nuclear extract was 
determined for the three different nuclear extracts. Data presenting the enzyme 
activity of three different experiments with VSMC, HeLa cells and HUVEC, each, 
are compiled in Table 12. 
 
Figure 6. Enzyme activity of VSMC, HeLa cells and HUVEC in U/mg, (statistics: 
one-way ANOVA, no significant difference, ns = p, n = 3) 
 
 
 
 
 
 
 
 
 
 
Table 12: Specific enzymatic activity in U/mg of single experiments with VSMC, 
HeLa cells and HUVEC nuclear extracts 
  protein, mg/ml Sp. activity, U/mg 
VSMC 2.10 1.86 
VSMC 2.00 1.57 
VSMC 1.96 1.82 
HeLa 2.25 1.82 
HeLa 2.14 1.69 
HeLa 2.14 1.69 
HUVEC 1.70 2.04 
HUVEC 1.12 1.57 
HUVEC 1.14 1.22 
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In conclusion, these experiments showed that the total HDAC activity of the three 
different sources for nuclear extract was similar and that these cell types can be 
used to study modulatory effects on HDAC activity. 
 
Due to the easy cultivation conditions of HeLa cells, the enzyme stability during 
storage and as well the high HDAC activity of the nuclear extract, HeLa nuclear 
extracts were used for further studies as a main source of HDAC.  
1 ml HeLa cells suspension at concentration 106 cells/ml were cultivated in a 60 
mm Petri dish with 12 ml DMEM medium, the cells grew rapidly and every 
second day HeLa nuclear extract was produced. 
 
D.1.3 Influence of Trichostatin A on the HDAC Activity 
 
Trichostatin A (TSA) is a well-characterized, very potent inhibitor of class I and 
class II HDACs. The IC50 values of TSA for HDAC 1, 3, 4, 6 and 10 were reported 
to be 4.99 nM, 5.21 nM, 27.60 nM, 16.40 nM and 24.30 nM, respectively, 
whereas for recombinant human HDAC 8 an IC50 of 486 nM was determined 
(Stefanko et al., 2009, Tatamyia et al., 2009).  
 
To confirm the results obtained with the HeLa nuclear extract prepared as 
described (C.7, page 34) we used trichostatin A as a positive control. 
 
In the set up used an IC50 value of 44.04 nM for TSA was determined (Figure 7, 
page 45). As the HeLa extract comprised a mixture of different HDACs and other 
proteins this IC50 value confirmed reliability of the assay. 
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Figure 7. IC50 value of TSA fot the HeLa nuclear extract in the HDAC assay 
(statistics: one-way ANOVA, no significant difference, n = 3) 
             r 2 = 0.9730 
 
 
 
 
 
 
 
 
 
 
 
 
To secure the optimal activity of the enzymes, the avoidance of many thawing 
and freezing cycles as well as storage of the nuclear extract at -80°C were self-
evident. Aliquots of 100 µl HeLa nuclear extracts were stored at -80°C and they 
were used only for one set of analyses at the same day.  
 
Overall, the nuclear extracts of HeLa cells proved to be a very good and easily 
accessible source of HDAC for the investigation of HDAC modulators. 
 
D.1.4 Incubation Time  
 
Incubation time of the enzyme with substrate is a crucial parameter for the 
enzymatic reaction.  
Different time courses were compared to determine the optimal incubation time in 
the assay-system. Different combinations of incubation time of the enzyme with 
the substrate in the first step I and further incubation of the samples with the 
activator solution in the second step II were monitored. The first set of 
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experiments was performed using 10 min incubation time for both steps. In the 
second experiment the incubation times were increased to 30 min for both steps, 
the third experiment was performed 45 min for step I and 30 min for step II. In a 
fourth set 60 min of incubation for step I was followed by 30 min for step II. The 
incubation times in experiment five were 60 min for both steps; experiment six 
was performed with 60 min incubation time in step I and 120 min in step II (Figure 
8). All experiments were performed three times in duplicates and appropriate 
blanks were subtracted. 
 
From the experiments was deduced that obviously after 60 min of incubation for 
each of the two steps a plateau in the reaction was reached. Thus, 60 min 
incubation times were used for all further experiments. 
 
Figure 8. Effect of different incubation times for step I and II on HDAC activity 
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D.1.5 Incubation Temperature 
 
Temperature during incubation and measurement was studied due to its strong 
influence on enzyme activity and stability.  
The experiments were performed at 22°C, 30°C and 37 °C at standard assay 
conditions (Figure 9). 
 
Figure 9. Enzyme activity in dependence of the incubation temperature (statistics 
two-tailed t-test vs 37 °C, ** = p < 0.005, n=3) 
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At 22°C the enzyme retained its activity and displa yed a satisfying velocity of the 
reaction. Thus, all further experiments were performed at 22°C. 
 
D.1.6 pH Optimum for HDAC Nuclear Extract 
 
The optimum pH and the influence of metal ions on HDAC activity had been 
studied by other groups (Mazitschek et al., 2008). Thus, pH of 7.8 was used in all 
experiments as recommended. The presence of potassium and sodium salts was 
essential for the enzyme activity and guaranteed by use of respective buffers. 
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D.1.7 Intra- and Inter-day Reproducibility 
 
Repeated intra-day (Figure 10) and inter-day (Figure 11, page 49) measurements 
were performed in order to investigate the reproducibility of the assay. For 
assessment of intra-day reproducibility three experiments were performed at 10 
and 12 a.m., and 4 p.m. (in duplicate, each).  
Inter-day reproducibility included measurements on three subsequent days. The 
experiments were performed in duplicate at 10 a.m., with three different lots of 
the HDAC source. 
 
Figure 10. Intra-day reproducibility 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard deviations of ±1.82% for the positive control TSA and ±5.10% for the 
enzyme incubated with substrate only were determined for intra-day 
measurements. 
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Figure 11. Inter-day reproducibility 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard deviations of ±2.60% for TSA and ±1.08% for the enzyme incubated 
with the substrate, respectively, were obtained for inter-day measurements.  
 
The values of intra- and inter-day analysis confirmed the excellent reproducibility 
of the HDAC assay. 
 
D.1.8 Influence of Autofluorescent Compounds on the Assay 
 
Due to the traditional use of the cortex from Viburnum opulus L. in cardiac 
complaints (VOLKSMED), extracts of this drug should serve as an example for 
the bioactivity-guided fractionation based on the HDAC assay. Four extracts of 
different polarity were prepared with CH2Cl2, EtOAc, MeOH and H2O (C.2.3, 
page 18). In the analyses of the extracts in the HDAC assay massive 
interferences were observed. It was not possible to determine the influence on 
HDAC activity. Therefore, TLC analyses were performed with the extracts. By 
detection under UV 365 nm several dark blue fluorescent zones with Rf values 
0.25, 0.34, 0.53, 0.66 and 0.85 were observed due to a high content of coumarin 
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derivatives (Figure 12). Obviously these compounds were responsible for the 
interferences. Viburni cortex contains scopoletin, scopolin, esculetin and 2’-p-
coumaroyl-dihyropenstemid as major constituents (Teuscher et al., 2009). 
 
Figure 12. TLC of CH2Cl2-, EtOAc- and MeOH- extracts from Viburni cortex. 
System 1 (C.3.3, page 22) and detection under UV 365 nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As autofluorescence of some compounds in complex plant extracts was a 
parameter which influenced the precision of the measurements, the assay had to 
be adapted. Thus, in analyses of extracts, the measurement of the 
autofluorescence of the tested mixtures in presence of substrate is an 
indispensable prerequisite for the application of the assay in bioactivity-guided 
approaches. 
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By analyses coumarin derivatives, such as esculetin or herniarin, massive 
interferences with the fluorophore AMC even at low concentrations 
(approximately 100 µM) were proven, which could lead to false positive results 
for HDAC modulation. Thus, all extracts under investigation in the HDAC assay 
have to be checked for dark blue-fluorescent substances in suitable thin layer 
chromatography (TLC) systems before testing in the assay, in order to avoid 
falsification of the results. 
 
Additionally, the assay has to include measurement for autofluorescence of the 
analyzed solution and the respective values have to be corrected. 
 
D.1.9 Amount of Organic Solvents Applicable in the Assay 
 
In the bioactivity-guided search for HDACm from plants, extracts of different 
polarity have to be studied. Thus, especially the solubility of apolar fractions or 
extracts for applicability in the assay had to be checked. 
 
DMSO is a universal solvent for various compounds with different polarity. The 
use of DMSO in cell culture is ubiquitous as well. Nevertheless, numerous 
studies have shown that the cells drastically react under its influence. Depending 
on the cell lines and cell types, as well as the applied DMSO concentration and 
the time of incubation, the process of differentiation and apoptosis are induced or 
blocked. The effectiveness of DMSO on cell differentiation process has been 
demonstrated by a large numbers of studies. The investigation of the cellular 
mechanism of DMSO on cell cycle is still unclear (Bolduc et al., 2001, Nickels, 
2004). 
 
The influence of DMSO on the HDAC assay was tested at concentrations of 1, 
1.25, 2, 2.5 and 5% (Table 13, page 52). The assay was robust against 5% 
DMSO. At all tested concentrations the modulation of the enzyme remained in 
the deviation of the method. 
Results 
 
 52 
Table 13: Influence of DMSO concentrations on the HDAC activity 
sample concentration,% activity,% 
DMSO 1% 1.00 108.0 
DMSO 1.25% 1.25 96.6 
DMSO 2% 2.00 111.4 
DMSO 2.5% 2.50 98.9 
DMSO 5% 5.00 112.8 
 
DMSO proved to be the superior solvent for the use in the HDAC assay due to its 
high potency to dissolve various plant extracts with different polarity.  
 
The assay substrate, AMC, TSA and all tested compounds were therefore 
dissolved in respective concentrations in DMSO and then diluted in a ratio 1:50 
with the assay buffer to final DMSO concentrations of 2%. 
 
Methanol was also tested as a solvent at concentrations of 1%, 2% and 5% to 
study its influence on HDAC assay. At concentrations of 1 and 2% it did not show 
any interactions with the enzymatic activity. The disadvantage of pure methanol 
was the poor solubility of several fractions. 
 
Thus, DMSO was chosen as the superior solvent and was further used for all 
tests. 
 
Although 2 to 5% DMSO can be added for the dissolution of extracts, fractions or 
pure compounds, the determination of the activity of very apolar primary and 
secondary plant metabolites such as fatty acids, sterols, carotenoids and fat-
soluble vitamins was not possible. Due to the fact that the maximum amount of 
DMSO in the assay is 5%, the incomplete solubility of these compounds in 
mixtures of DMSO and assay buffer prevented the measurements. 
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D.1.10 Influence of Different Classes of Natural Compounds on the 
HDAC Assay 
 
To exclude interferences of other substances with the HADC assay, the influence 
on HDAC activity of primary and widespread secondary plant metabolites, such 
as sugars, vitamins, amino acids, phenolic and organic acids, tannins, 
chlorophyll, pigments etc. which are common and abundant constituents in 
extracts, were studied.  
Monosaccharides such as glucose and fructose or the disaccharide saccharose 
at concentrations of 1 mM showed no obvious interference of sugars with the 
assay.  
Chlorophyll (chlorophylla 420 µM, chlorophyllb 350 µM) as well as other plant 
pigments e.g. purpurin (630 µM) did not affect the measurement as well.  
Solutions of various organic acids like citric, ascorbic, gallic, salicylic, cinnamic, 
caffeic, ferulic, vanillic or isovanillic acids (1 mM) did not interfere with the assay. 
The modulatory effect of some amino acids was studied at a concentration of 1 
mM. The experiments were performed with nonpolar amino acids like alanine, 
methionine and glycine, polar amino acid e.g. arginine, and slightly polar amino 
acids such as cysteine and tryptophan. The results showed that at the tested 
concentration (1 mM) the influence on HDAC activity was marginal, appr. 5 % 
inhibition was determined. 
 
The inhibitory potential of water-soluble vitamins was studied as well. Several 
representatives of the group of B vitamins (thiamine, riboflavin, niacin and 
nicotinamide, pyridoxine and pyridoxal, folic acid, and cyanocobalamin) at 
concentrations of 1 mM were tested and did not show an inhibitory effect. 
 
Ubiquitous flavonoids such as hyperoside, rutin and quercetin influenced the 
activity of the histone deacetylases only at higher micromolar concentrations. 
IC50 values of 603 µM, 420 µM and 560 µM, respectively, were determined. Less 
widespread flavonoids and phenols such as apigenin, chrysin, saponarin, 
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myricetin, myricitrin, taxifoline, catechin, epicatechin, biochanin A, daidzein, 
daidzin, formononetin, genistein, glycitein or glycitin showed no or only very 
marginal inhibitory effects at concentrations between 350 µM to 1 mM. Other 
phenolic compounds such as chlorogenic acid (1 mM) or verbascoside (400 µM) 
did not influence the HDAC activity. 
 
For tannic acid and catechin gallate an inhibitory influence on HDAC activity at a 
concentration of approximately 300 µM was observed. This effect was due to an 
obvious precipitation of proteins and not a direct inhibition of the enzymatic 
activity.  
Due to the observed effects of tannic acid and catechin gallate the general 
applicability of the assay to plant extracts which contain tannins had to be 
checked. For this purpose an aqueous extract of Ratanhiae radix (C.2.2, page 
18) was prepared and tested, as this drug contains up to 15% tannins (Blaschek 
el al., 2009).  
The aqueous extract displayed an inhibitory effect on HDAC activity, with an IC50 
of approximately 545 µg/ml. This inhibition, however, was again due to 
precipitation of the HDAC proteins. This was confirmed by the preparation of a 
detannified extract (C.2.2, page 18), which showed an inhibition of approximately 
25% at a concentration of 10 mg/ml (Figure 13, page 55).  
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Figure 13. Influence of tannin content on HDAC activity 
 
    n = 2     n = 2 
 
These findings confirmed the expected fact that tannins strongly inhibit HDAC 
activity due to precipitation of the enzymes. In order to avoid false positive results 
detannification of extracts rich in tannins before testing is indispensable. 
 
D.2 Screening of Secondary Plant Metabolites for their 
Potential for HDAC Modulation 
 
After the comprehensive validation of the fluorimetric HDAC assay several 
secondary plant compounds were selected due to their structural diversity and 
their relationship to known HDAC inhibitors for a screening. 
 
D.2.1 Anthraderivatives 
 
In some cancer treatments (leukemia, lymphomas, breast and esophageal 
carcinomas, osteosarcomas, Kaposi’s sarcoma, soft tissue, testicular, gastric, 
ovarian, liver, bile-dict, pancreatic and endometrial carcinomas) doxorubicin, an 
anthraderivate, is a powerful chemotherapeutic (Christiansen and Autschbach, 
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2006). Its mechanism of action is a direct interaction with DNA by intercalation. 
Recently, it was shown that some HDACi, e.g. valproic acid, increased the 
sensitivity of osteosarcoma to doxorubicin. The integration of HDACi into 
cytotoxic therapy against cancer might lead to more specific cancer treatment 
(Wittenburg et al., 2010). 
 
Due to these facts the influence of three types of anthraderivatives on HDAC 
activity was studied and IC50 values were determined. The aloines aloin A (IC50 
270 µM) and B (IC50 300 µM), the anthraquinones aloeemodin (IC50 420 µM) and 
emodin (IC50 370 µM) showed activity in the HDAC assay. The best effect was 
achieved with the dianthrones sennoside A (IC50 180 µM) and B (IC50 220 µM), 
although as well at micromolar concentrations only. 
These results pointed to a better activity of those anthraderivatives in which C10 
is blocked by a C-C bond. 
 
D.2.2 Alkaloids, Betaines and Cardiac Glycosides 
 
In contrary to these anthraderivatives, alkaloids like atropine, berberine, boldine, 
caffeine, cephaeline, chelidonine, quinine, emetine, eserine, papaverine, cardiac 
glycosides like digitoxin or gitoxin, and betaines like stachydrine or betonicine 
remained without effects up to concentrations of 400 µM. 
 
D.2.3 Ginkgolic Acids 
 
Due to the reports of inhibition of tumor cell proliferation by ginkgolic acids (Yang 
at al., 2004) a set of ginkgolic acids (Table 14, page 57) kindly provided by Dr. E. 
Koch (Dr. Willmar Schwabe GmbH & Co. KB, Karlsruhe, Germany) was tested 
for a modulatory effect on the HDAC activity. 
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Table 14: Ginkgolic acids tested in the HDAC assay 
Code Chemical structure MW  CAS No. 
GS-001 O
OH
OH
 
374.57 C24H38O3 111047-30-4 
GS-002 O
OH
OH
 
346.51 C22H34O3 22910-60-7 
GS-003 O
OH
OH
 
346.51 C22H34O3 110202-77-2 
GS-004 O
OH
OH
 
348.53 C22H36O3 16611-84-0 
GS-005 O
OH
OH
 
320.48 C20H32O3 20261-38-5 
GS-007 O
OH
OH
 
374.57 C24H38O3 69506-63-4 
GS-008 O
OH
OH
 
376.58 C24H40O3 20261-39-6 
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The samples were analyzed in duplicates at concentrations of 1 mg/ml. The 
results showed that the ginkgolic acids did not posses modulatory activity on the 
enzymatic activity at this concentration, Table 15. 
 
Table 15: Influence of ginkgolic acids on HDAC activity (n = 2) 
Sample concentration, mM activation, % 
GS-001 0.68 17.9 
GS-002 0.73 7.6 
GS-003 0.73 9.7 
GS-004 0.73 4.9 
GS-005 0.78 1.3 
GS-007 0.68 1.3 
GS-008 0.65 2.4 
 
At the standard assay conditions the ginkgolic acids were not potential HDAC 
modulators.  
 
D.2.4 Comparison of in silico HDAC Inhibition with the in vitro HDAC 
Assay 
 
An in silico model has been developed by the research group of the Center for 
Molecular Biosciences Innsbruck, University of Innsbruck, for the search for 
HDAC inhibitors. According to the developed in silico model 27 pure compounds 
(indicated from 1 – 27) and 6 plant extracts (named A – F) were selected as 
potent inhibitors. To check the validity of the theoretical approach these 
compounds and extracts were tested in the HDAC assay (Table 16, page 59).  
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Table 16: Inhibitory effect of in silico hits in the in vitro HDAC assay in % 
N  Abbreviation 10µM 25µM 50µM 100µM 250µM 10mg/ml 
        
1 NSC31965 0.0 0.0 0.0 13.5 23.6  
2 NSC34781 0.0 0.0 1.2 9.5 45.1  
3 NSC73831     0.0  
4 NSC96573 0.0 0.0 0.0 0.0 21.9  
5 NSC137222 0.0 0.0 0.0 0.0 35.0  
6 NSC162709 7.7 0.0 13.9 39.2 79.9  
7 NSC168195 25.8 13.6 12.8 40.9 42.5  
8 NSC169682 18.4 13.3 23.0 26.3 43.1  
9 NSC201876     1.6  
10 NSC211822 13.8 12.1 3.1 6.1 18.1  
11 NSC222548     0.0  
12 NSC222549     0.0  
13 NSC305740     0.0  
14 NSC311481     2.3  
15 NSC321073 19.5 20.8 12.0 7.6 20.5  
16 NSC328022 14.6 8.0 21.1 27.8 17.8  
17 NSC328131     0.0  
18 NSC347462     7.5  
19 NSC353484 39.0 19.0 17.4 29.2 49.4  
20 NSC618567     5.8  
21 NSC618689     6.9  
22 NSC618800 0.0 2.4 0.0 0.0 22.2  
23 NSC623869     5.5  
24 NSC623876     8.7  
25 NSC630366     0.0  
26 NSC640959     13.0  
27 NSC668820     5.2  
A Lin-str-rd 1      3.7 
B Lin-str-rd 2      33.6 
C Leo-het-hb 1      0.0 
D Leo-het-hb 2      3.4 
E Spa-sub-hb 1      27.0 
F Spa-sub-hb 2      45.6 
 
All compounds were tested at 250 µM, whereas the concentration of the extracts 
in the assay was 10 mg/ml in the first screening. Compounds with an inhibitory 
effect higher than 20% were tested further at concentrations of 100 µM, 50 µM, 
25 µM and 10 µM.  
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The compounds 2, 6, 7, 8, and 19 at a concentration of 250 µM showed the 
strongest effect with 45.1%, 79.9%, 42.5%, 43.1%, and 49.4% inhibition, 
respectively. Compound 6 was the most potent. Thus, this substance was further 
investigated and an IC50 value of 115 µM was determined.  
Extract F (Spa-sub-hb 2) at a concentration of 10 mg/ml exhibited an HDAC 
inhibition of 45.6%. 
 
The chemical structures of the tested compounds are shown in Supplements, 
page 138. 
 
The low HDAC inhibitory potential of the in silico hits can be explained by the fact 
that the in silico system was established for a study of the isoform HDAC 8, 
whereas in the in vitro assay HeLa nuclear extract was used as source of 
HDACs. Due to lack of detailed information on the content of HDAC 8 in the 
HeLa nuclear extract a close correlation of the in silico results to the in vitro 
results was not achieved. Nevertheless, some of the tested compounds seem to 
be potential inhibitors to other HDAC isoforms as well. 
 
D.2.5 Effect of TCM Decoctions on the HDAC Activity 
 
A preparation of traditional Chinese medicine is currently under investigation in a 
model of experimental cardiac infarction in mice. The verum group received a 
decoction prepared from the roots of Glycyrrhiza uralensis Fisch, the tubers of 
Aconitum carmichaeli Ross, the rhizomes of Zingiber officinale Debx. and the 
bark of Cinnamomum cassia Nees instead of water. It was observed that in the 
verum group survival rate was significantly higher than in untreated control (Ma, 
unpublished data). 
 
Analyses of the decoctions of the single herbs, indicated as TCM 1 to TCM 4 and 
TCM 5 for the mixture, were performed and different effects were observed 
(Figure 14 and Table 17).  
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Figure 14. Effect of single drugs and TCM mixtures on HDAC activity (statistics: 
two-tailed t-test vs TCM5, ** = p < 0.0088, *** = p < 0.0001, n = 3) 
 
 
 
 
 
 
 
 
 
 
 
    
 
Table 17: Influence of TCM herbs on HDAC activity 
 code  herb concentration, mg/ml inhibition, % activity, % 
TCM1 Glycyrrhiza 2.1 17.1  
TCM2 Zingiber 1.9   
TCM3 Aconitum 1.9   
TCM4 Cinnamomum 1.8  17.5 
TCM5 TCM mixture 2.2  36.5 
 
TCM 1 showed an inhibitory effect whereas TCM 2 and TCM 3 had no effect on 
HDAC activity. In contrary a slightly activating effect of TCM 4 and a more 
pronounced one was observed for TCM 5. 
 
D.2.6 Effect of Natural Compounds on HDAC1, HDAC2 and HDAC3 
Activity in vitro 
 
Due to HDAC inhibiting activity of aloines (aloin) and dianthrones (sennosides A 
and B) and the structural diversity of capsaicin, rutin, stachydrine and 
verbascoside they were further investigated. At concentrations of 50 µM the pure 
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compounds were tested for an inhibitory effect in a homogeneous system with 
recombinant pure enzymes HDAC1, HDAC2 and HDAC3. Only sennoside A 
showed inhibition of 40% on isoform HDAC3 at a concentration of 50 µM. The 
extract of Leonuri herba and the fractions SPE F2, F3, F4 at concentration of 50 
µg/ml were studied for their effect as well. The experiments were performed in 
triplicates. Appropriate blanks were subtracted from the values. 
 
D.3 Bioactivity-Guided Fractionation of an Extract from 
Leonuri herba 
 
To investigate the applicability of the adapted and validated assay for bioactivity-
guided fractionations of plant extracts in addition to the study of different pure 
plant compounds, the optimized assay was further tested on extracts of Leonuri 
herba. 
 
Leonuri herba, due to its traditional use against cardiac complaints was selected 
as an example. Extracts of different polarity were prepared. The extraction was 
performed with 9 g plant material (see C.2.4, page 20) and yielded CH2Cl2-, 
EtOAc-, MeOH- and H2O extracts. 
 
These extracts were tested at concentrations of 10 mg/ml for HDAC inhibition. 
The methanolic extract was the most active (Figure 15, page 63). Nevertheless, 
its activity was significantly lower than the one of 1 µM TSA. 
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Figure 15. Effect of extracts from Leonuri herba on HDAC activity (statistics: two-
tailed t-test vs positive control 1µM TSA, * = p < 0.026, ** = p < 0.051, *** = p < 
0.0005, n = 3) 
 
 
 
 
 
 
 
 
 
 
 
The composition of the extracts was investigated by TLC analyses. After 
detection with anisaldehyde sulfuric acid reagent in the dichloromethane extract 
mainly terpenoid compounds with Rf values 0.43, 0.47, 0.86 and 0.92 were 
detected. In the methanolic extract two pronounced green bands at Rf 0.33 and 
0.52 were detected (Figure 16, page 64). Under UV 365 nm red fluorescent 
bands of chlorophyll were visible in the dichloromethane, ethyl acetate, and 
methanolic extracts with Rf values between 0.66 and 1. 
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Figure 16. TLC of the different extracts from Leonuri herba, system 1 (page 23) 
and detection at day light after spraying with anisaldehyde sulfuric acid reagent 
and under UV 365 nm  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the amount of chlorophyll in the methanolic extract, these accompanying 
compounds had to be removed and the methanolic extract was further 
investigated after chlorophyll separation (see C.2.6., page 19). The chlorophyll 
removal was successfully performed in step I by partition between water and 
chloroform and subsequently water and ethyl acetate, in step II (C.2.6, page 19). 
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TLC analyses were used to confirm that the chlorophyll was mainly enriched in 
the chloroform phase (Figure 17). The intensive red colored zones with Rf values 
of 0.9 to 1 confirmed that the partition with chloroform was effective for the 
removal of chlorophyll. 
 
Figure 17. Chlorophyll separation steps of the MeOH extract, system 1 (C.3.3, 
page 23) and the detection under UV 365 nm after spraying with NEU reagent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MeOH is original methanolic extract obtained by extraction of the drug with 
methanol, CR CHCl3 are the combined chloroform phases after double partition 
of the methanolic extract with water and chloroform, CR EtOAc ethyl acetate 
phases after double partition with water and ethyl acetate, the remaining aqueous 
phase was indicated CR H2O. 
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The extracts MeOH, CR CHCl3, CR EtOAc and CR H2O obtained after 
chlorophyll removal were additionally analyzed by HPLC, see Figures 18-21, 
pages 66-68.  
 
Figure 18. HPLC of the methanolic extract from the drug (MeOH), system 1 
(page 24), gradient program 1 (page 24), detection at 254 nm 
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Figure 19. HPLC of CR CHCl3, system 1 (page 24), gradient program 1 (page 
24), detection at 254 nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. HPLC of CR EtOAc, system 1 (page 24), gradient program 1 (page 
24), detection at 254 nm 
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Figure 21. HPLC of CR H2O, system 1 (page 24), gradient program 1 (page 24), 
detection at 254 nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The HPLC analyses confirmed that by liquid partition of the methanolic extract 
between water and chloroform and water and ethyl acetate, the phenolic 
compounds were enriched in the aqueous phase. Some apolar compounds e.g. 
oily matters, terpenes and chlorophyll were removed from the methanolic extract. 
 
D.4 Identification of Compounds in Fraction CR H2O from 
Leonuri herba 
 
TLC was used to identify the phenolic compounds in fraction CR H2O from 
Leonuri herba. Rutin, caffeic acid, chlorogenic acid and hyperoside were 
compared with the compounds in the extracts. It was possible to confirm that the 
two orange zones in the extract as rutin (Rf= 0.38) and hyperoside (Rf= 0.56). 
The whitish fluorescent zone with a Rf value of 0.40 revealed chlorogenic acid, 
Figure 22, page 69. 
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Figure 22. TLC analysis of fractions CR H2O, F2 and F3 with phenolic acids and 
flavonoides, system 2 (page 22), detection under UV 365 after spraying with NEU 
reagent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standards rutin, caffeic acid (CA), chlorogenic acid (CClA), rosmarinic acid (RA) 
and hyperoside (Hyp) were used to elucidate the composition of fractions F2, F3 
and CR H2O. 
Further, by TLC analysis verbascoside (VS) was confirmed in fraction CR H2O 
with Rf value 0.54 (Figure 23, page 70).  
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Figure 23. TLC analysis of fraction CR H2O with verbascoside (VS), system 2 
(page 22), detection under UV 365 nm after spraying with NEU reagent 
 
 
 
 
 
 
 
 
 
 
 
Fraction CR H2O additionally contained glucose (Glu) with a Rf value of 0.83, 
fructose (Fru) with a Rf value of 0.83 and rhamnose (Rha) with a Rf value of 0.9. 
Mannose (Mann) was not detected (Figure 24). 
 
Figure 24. Sugar analysis by TLC of fraction CR H2O, system 3 (page 23), 
detection at day light after spraying with anisaldehyde sulfuric acid reagent 
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D.5 Analysis of the SPE Fractions 
 
After chlorophyll removal from the methanolic extract fraction CR H2O was 
submitted to fractionation by SPE and five fractions F1 to F5 were obtained. 
 
D.5.1 HDAC Assay 
 
The fractions F1, F2, F3, F4 and F5 obtained by SPE were investigated for their 
effect on HDAC activity at concentrations of 1 mg/ml.  
The fraction F3 showed the highest potential to inhibit HDAC activity with 76% 
inhibition at 1 mg/ml. The effect was comparable to 1 µM TSA. Weak activity was 
detemined for fraction F4, whereas fractions F1, F2 and F5 remained without 
effect (Figure 25).  
 
Figure 25. Effect of SPE fractions on HDAC activity (statistics: two-tailed t-test vs 
positive control 1µM TSA, ** = p < 0.0017, *** = p < 0.0007, n = 3) 
 
 
 
 
 
 
 
  
 
 
 
D.5.2 TLC Fingerprinting 
 
In order to get detailed information about the chemical composition of the 
fractions they were characterized by TLC (Figure 26, page 73) 
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In TLC fingerprinting of the SPE fractions focusing on phenolics the original 
fraction CR H2O showed three major whitish blue fluorescent compounds with Rf 
values 0.64, 0.89 and 0.98 under UV 365 nm after sraying with NEU reagent. 
Two of these compounds were enriched in fraction F2. Detection at day light after 
spaying with anisaldehyde sulfuric acid reagent revealed high amounts of polar 
compounds in CR H2O. In F1 three major compounds with Rf values of 0.72 (blue 
zone), 0.78 (green zone) and 0.98 (blue-green zone) were observed under UV 
365. Detection at day light after spaying with anisaldehyde sulfuric acid reagent 
showed high amounts of polar compounds with Rf < 0.23 in F1, presumably 
sugars. Besides the two fluorescent major compounds with Rf values 0.64 and 
0.89 F2 additionally contained various compounds of medium polarity (Rf= 0.24, 
0.32, 0.41, 0.55 and 0.67). Three characteristic orange fluorescent zones were 
detected in fraction F3, presumably flavonoid compounds with Rf values 0.67, 
0.78 and 0.81. Day light detection with the anisaldehyde sulfuric acid reagent 
showed a complex mixture of polar compounds. Fractions F4 and F5 contained 
mainly apolar substances.  
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Figure 26. TLC fingerprint of SPE fractions. System 1 (page 22) and detection 
under UV 365 nm after spraying with NEU reagent and at day light after spraying 
with anisaldehyde sulfuric acid reagent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D.6 Separation of F3 by CPC 
 
Centrifugal Partition Chromatography is excellently suitable for the separation of 
flavonoid mixtures (Green, 2007). To avoid any loss of active compounds this 
method was chosen for the further fractionation of F3. For this purpose 86.0 mg 
F3 were dissolved in ethyl acetate-water and separated (see C.3.1, page 21). 
Fractions were collected, each fifth fraction was characterized by TLC and 
according to the similarity in chemical composition the fractions were pooled. The 
combined fractions of CPC1 were named from A1 to U1. The yields are presented 
in Table 18, page 74 and the TLC analyses of the combined fractions are given in 
Figure 27, page 75. 
    F1  F2 F3 F4     F5 CR H2O    F1     F2 F3    F4     F5  CR H2O 
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Table 18: Yields of CPC1 fractions 
pooled fraction single fractions mg 
A1 1-13 1.70 
B1 14 0.42 
C1 15-18 1.78 
D1 19-20 0.54 
E1 21-23 0.44 
F1 24-26 0.55 
G1 27-31 1.15 
H1 32-36 0.99 
I1 37-43 1.45 
J1 44-46 0.54 
K1 47-52 1.15 
L1 53-56 1.13 
M1 55-62 2.35 
N1 63-70 1.69 
O1 71-72 1.13 
P1 73-76 1.57 
Q1 77-80 12.72 
R1 81-83 4.02 
S1 84-86 12.96 
T1 87-89 24.24 
U1 90-92 0.34 
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Figure 27. TLC of CPC fractions, system 1 (page 22), detection under UV 365 
nm after spraying with NEU reagent and at day light after spraying with 
anisaldehyde sulfuric acid reagent 
  A1   B1   C1  D1   E1   F1  G1    H1     I1    J1    K1   L1  M1  N1   O1   P1    Q1   R1    S1     T1    U1   F3 
A1      B1     C1    D1      E1    F1      G1    H1      I1     J1       K1      L1    M1      N1   O1    P1      Q1     R1    S1        T1     U1  F3 
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Fraction C1 revealed a major greenish compound under UV 365 nm, which 
appeared pale greenish after detection with anisaldehyde sulfuric acid reagent at 
day light with Rf value 0.78. Fraction F1 showed two yellowish fluorescent zones 
under UV 365 nm with Rf values 0.67 and 0.72, which after spaying with 
anisaldehyde sulfuric acid reagent at day light appeared pale greenish. Fractions 
G1 showed a blueish fluorescent compound under UV 365 nm with Rf value 0.83, 
which after anisaldehyde sulfuric acid reagent was indicated as a dark green 
zone. A compound with similar characteristics was detected in fraction M1. 
Additionally in fraction G1 a second blueish fluorescent compound was visible 
under UV 365 nm (Rf value 0.68), which was hardly detectable with anisaldehyde 
sulfuric acid reagent at day light. Fraction I1 revealed a major greenish 
fluorescent compound under UV 365 nm with a Rf value of 0.59, which had a 
greenish color after spraying with anisaldehyde sulfuric acid reagent at day light 
observation. Fraction O1 showed diverse green zones under UV 365 nm, the 
detection with anisaldehyde sulfuric acid reagent at day light revealed three 
major compounds with Rf values 0.11, 0.24, 0.43. In fraction P1 an intensive 
greenish fluorescent compound with Rf value 0.59 was detected under UV 365 
nm. Fraction Q1 contained a major whitish fluorescent compound with Rf value of 
0.77. Fraction R1 showed one major compound with orange fluorescence and a 
Rf value of 0.48, at day light after applying anisaldehyde sulfuric acid reagent 
these substances in R1 and Q1 showed greenish color. Fraction S1 contained as 
well one major compound with a Rf value of 0.48, but under UV 365 nm it 
showed white fluorescence and after spraying with anisaldehyde sulfuric acid 
reagent revealed a dark green zone. Fraction T1 was a mixture of highly whitish 
fluorescent compounds, the major of them had a Rf of approximately 0.42, the 
same compound appeared in fraction U1. The orange band with Rf= 0.3 in 
fraction T1 with Rf= 0.48 in fraction R1 were identified as rutin and hyperoside, 
respectively. The strong whitish fluorescent compound in fractions T1, and U1 
was chlorogenic acid (Rf= 0.42) (Figure 22, page 69). Isochlorogenic acid with 
Rf= 0.77 was tentatively identified in fraction Q1 (Wagner and Bladt, 1996). 
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Fractions O1 to U1 were additionally analyzed by HPLC and as well their effect on 
HDAC activity was monitored. The most potent fractions were R1 and T1, 
showing HDAC inhibition of appr. 90% and 87% at concentrations of 5.5 mg/ml 
and 5.7 mg/ml, respectively (Figure 28), which at these concentrations were not 
significantly different from 1 µM TSA. 
The effect of fractions A1 to N1 could not be monitored in the assay due to 
problems with solubility in the assay buffer. 
 
Figure 28. Effect of CPC1 fractions on HDAC activity (statistics: two tailed t-test 
vs positive control 1 µM TSA, ns = p = 0.15 (R) and 0.06 (T), ** = p = 0.04, *** = p 
< 0.0001, n = 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the strongest inhibitory effect of fractions R1 and T1, further investigations 
were performed with these fractions. 
 
HPLC analysis of fraction R1 showed two major peaks at Rt 11.39 and 11.82 with 
identical UV spectra with maxima at 256 nm and 354 nm (Figure 29, page 78). 
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Figure 29. HPLC analysis of fraction R1 and UV spectra of the two major 
compounds. System 1 (page 24), gradient program 1 (page 24), detection at 254 
nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
UV spectra at Rt 11.39 and 11.82 
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In order to collect more material for further analyses of the fractions R and T a 
second separation of 80 mg F3 by CPC was performed. Based on TLC analyses 
of each fifth fraction those with similar profile were pooled. The combined 
fractions of CPC2 were named again from A2 to U2. The yields are presented in 
Table 19.  
 
Table 19: Fractions collected by CPC2 
 pooled fraction  single fraction  mg 
A2 1-12 2.50 
B2 13 0.32 
C2 14-18 1.72 
D2 19-20 0.58 
E2 21-23 1.06 
F2 24-26 1.14 
G2 27-30 1.68 
H2 31-34 1.03 
I2 35-43 1.73 
J2 44-47 0.56 
K2 48-52 1.88 
L2 53-56 1.59 
M2 57-61 2.26 
N2 62-70 2.30 
O2 71-72 1.55 
P2 73-76 3.07 
Q2 77-80 13.20 
R2 81-84 4.51 
S2 85-86 7.76 
T2 87-89 7.24 
U2 90-93 7.27 
 
Detailed analyses of fractions R1 and R2 were performed by TLC. Two intensive 
fluorescent orange zones were detected with Rf values of 0.60 and 0.62 (Figure 
30, page 80). The use of authentic standard rutin (Rf= 0.62) confirmed the more 
apolar zone as rutin, whereas the more polar one was an unknown compound.  
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Figure 30. TLC of the subfractions 82 and 83 of fraction R (CPC1,2), system 2 
(page 22), detection under 365 nm after spraying with NEU reagent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fractions R1 and R2 were additionally analyzed by HPLC and each of them 
showed two compounds, the unknown (Rt= 11.39) and rutin (Rt= 11.89) at 
different concentrations.  
 
HPLC analysis of subfraction 822 revealed a higher concentration of the unknown 
compound (Figure 31, page 81). In subfraction 832 the rutin concentration was 
higher (Figure 32, page 82). 
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Figure 31. HPLC analysis of subfraction 822 and UV spectra of the two major 
compounds. System 1 (page 24), gradient program 1 (page 24), detection at 254 
nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UV spectra at Rt 11.39 and 11.82 
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Figure 32. HPLC analysis of subfraction 832 and the UV spectra of its two major 
peaks. System 1 (page 24), gradient program 1 (page 24), detection at 254 nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UV spectra at Rt 11.39 and 11.89 
 
 
 
 
 
 
 
 
 
 
As a second potent fraction T was further analyzed. T1 was a pool of subfractions 
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89 from CPC2 (Table 19, page 79). HPLC analysis showed one major compound 
with Rt 13.79 and a UV maximum at 330 nm (Figure 33). 
 
Figure 33. HPLC analysis of fraction T and UV spectrum. System 1 (page 24), 
gradient program 1 (page 24), detection at 254 nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
UV spectrum at Rt 13.79 
 
 
 
 
 
 
 
 
The total yield of T (T1 + T2) was 31.4 mg. Due to the similarity in the composition 
of fractions T and U were combined to fraction “TU” with a total amount of 38.9 
mg. This sample was loaded on a Sephadex LH 20 column and eluted with 
water. 80 fractions with a volume of 2 ml were collected and lyophilized.  
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D.7 Column Chromatography - Preparative Scale 
 
As the amount of fraction TU was too low to isolate the active compound, a 
higher amount of fraction CR H2O extract (60 g) had to be fractionated. Due to 
the very high cost of SPE in such a scale column chromatography on Sephadex 
LH 20 (SCC) was the method of choice. The extract was fractionated in two 
portions of 30 g, each. The elution was started with water and continued with 
increasing portions methanol at a rate of 40 ml/h. F1 was used to indicate 
fractions eluted with water, F2 with 20% methanol, F3 with 40% methanol, F4 
with 80% and F5 with 100% methanol. The fractions were analyzed, according to 
the similar composition pooled and the yields are presented in Table 20. 
 
Table 20: SCC fractions after separation on a Sephadex LH 20 column 
SCC fractions mg 
SCC F1a 16700.0 
SCC F1b 1690.0 
SCC F1c 177.6 
SCC F1d 1640.0 
SCC F1e 102.2 
SCC F2a 695.2 
SCC F2b 1560.0 
SCC F2c 85.5 
SCC F2d 127.4 
SCC F2e 918.0 
SCC F3a 654.3 
SCC F3b 441.0 
SCC F3c 329.3 
SCC F3d 131.0 
SCC F3e 311.4 
SCC F4a 54.5 
SCC F4b 53.5 
SCC F4c 45.8 
SCC F4d 17.9 
SCC F4e 123.7 
SCC F5a 51.5 
SCC F5b 37.5 
SCC F5c 7.1 
SCC F5d 9.3 
SCC F5e 8.4 
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The SCC F2, 3, 4 and 5 fractions were studied at a concentration 1 mg/ml for 
their modulatory effect on the HDAC activity. The results are presented in Figure 
34. 
 
Figure 34. Effect of SCC F2, 3, 4 and 5 fractions on the HDAC activity, n = 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fraction SCC F2 showed a modulatory effect on HDAC activity from 50% to 70%. 
Fractions SCC F3a and SCC F3c showed inhibition of 65% and 77%, 
respectively, whereas the rest of SCC F3 fractions showed approximately 50% 
inhibition. Generally all SCC F4 fractions showed strong inhibitory effect between 
70% and 75%, due to lack of time the detailed investigation was not performed. 
SCC F5 fractions demontrated a slight inhibitory effect on the HDAC activity or 
remained without effect. 
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In order to investigate the chemical composition of several SCC fractions SCC 
F2e, SCC F3a, SCC F3b, SCC F3c, SCC F3d and SCC F3e, they were further 
characterized by TLC (Figure 35). 
 
Figure 35. SCC selected fractions, system 1 (page 22), detection at day light 
after spraying with anisaldehyde sulfuric acid reagent and under UV 365 nm after 
spraying with NEU reagent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fraction SCCF 3a showed a major green fluorescent zone with Rf value 0.30, 
additionally compounds at low concentrations with Rf values of 0.22, 0.26, 0.38 
and 0.61 were detected under UV 365 nm and sraying with NEU reagent. The 
TLC plate after spraying with anisaldehyde reagent and detection at day light 
revealed one major compound with a Rf value of 0.3. In fraction SCC F3b several 
green and two blue fluorescent compounds with Rf values of 0.22, 0.26, 0.30, 
0.44, 0.52 and 0.61 (green fluorescent), 0.34 and 0.38 (blue fluorescent) were 
  SCCF3a  SCCF3b  SCCF3c SCCF3d SCCF3e SCCF2e       SCCF3a SCCF3bSCCF3cSCCF3dSCCF3eSCCF2e 
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observed. The observation at day light revealed four greenish compounds with Rf 
values 0.22, 0.30, 0.34 and 0.38. SCC F3c and SCC F3d showed almost 
identical profiles, three green fluorescent zones with Rf values 0.26, 0.56, and 
0.67 which were detected as green zones as well at day light after spraying with 
anisaldehyde sulfuric acid reagent. SCC F3e showed green (Rf= 0.16, 0.19, 0.26, 
0.30 and 0.34) and blue (Rf= 0.43 and 0.49) fluorescent zones and one orange 
band (Rf= 0.56). Fraction SCC F2e contained one major compound with a Rf 
value of 0.30, detected with both systems. Due to its potential to modulate HDAC 
activity fraction SCC F3c was used for further isolation of a pure compound. 
 
D.8 Semi-Preparative HPLC 
 
In order to isolate and characterize the major compound in fraction SCC F3c
 
a 
semi-preparative HPLC was performed, according to the C.3.5, page 25.  
 
60 mg of SCC F3c were separated by HPLC on a Nucleosil column eluting with 
40% MeOH and increasing the solvent polarity from 40% to 95% MeOH within 20 
minutes. 33 fractions with volume of 17 ml were collected (Figure 36, page 88). 
Fractions 7 and 8 were pooled, lyophilized and indicated as SPH L fraction.  
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Figure 36. HPLC of SCC F3c and UV spectrum of SPH L fraction, gradient 
program 4 (page 26), detection at 215 nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
UV spectrum at Rt 4.57 
 
 
 
 
 
 
 
 
The UV spectrum of SPH L which showed two maxima 197 and 331 nm, 
respectively. HPLC analysis of SPH L showed a high purity of the compound 
(Figure 37, page 89) which was further analyzed by LC-MS (Figure 38, page 90) 
and finally characterized by NMR (Figures 39-40, pages 91-92). 
 
The 1H- and 13C NMR shifts were in excellent correlation with those of 
lavandulifolioside (Calis at al., 1992). This compound has been described in 
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Leonurus cardiaca before (Milkowska-Leyck at al, 2002). The MS results 
confirmed the structure by the molecular ion of 755.4 in the negative mode and 
the fragments with a molecular weight of 593.4, 461.3, 315.2 and 135.1 m/z are 
representing signals for the caffeoyl, arabinose, rhamnose and glucose moieties 
of lavandulifolioside, respectively (Figure 38, page 90). 
Thus, the structure was unambiguously elucidated as lavandulifolioside. The 
yield of lavandulifolioside was 33 mg.  
 
Figure 37. HPLC of SPH L fraction and its UV spectrum, system 2 (page 24), 
gradient 2 (page 24), detection at 254 nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
UV spectrum at Rt 11.74 
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Figure 38. LC-MS analysis of lavandulifolioside 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* The LC-MS measurements were performed by Dr. Martin Zehl, Department for Pharmacognosy, University of Vienna. 
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Figure 39. 1H NMR analysis of lavandulifolioside 
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Figure 40. 13C NMR analysis of lavandulifolioside 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* The NMR measurements were performed by Ass. Prof. Hanspeter Kaehlig, Institut of Organic Chemistry, University of 
Vienna. 
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The influence of lavandulifolioside on HDAC activity was studied and an IC50 of 
220 µM was determined.  
 
Although lavandulifolioside is not a highly potent HDAC inhibitor, these results 
impressively confirmed the applicability of the assay for the successful and 
efficient bioactivity-guided isolation of HDAC modulators from plant origin. 
 
To sum up, the used chromatographic methods (TLC and HPLC) revealed rutin, 
hyperoside, chlorogenic and isochlorogenic acids, verbascoside and 
lavandulifolioside as major phenolic compounds and as well the sugars glucose, 
fructose and rhamnose. Further phenolic acids and flavonoids were not identified 
due to the lack of respective standards. 
 
D.9 Influence of Natural Compounds on HeLa Cells 
Proliferation 
 
Several compounds e.g. aloin, capsaicine, rutin, stachydrine, sennosides A and 
B, verbascoside, as well fractions CR H2O, SPE F2, F3 and F4, which have 
shown some effects in the enzymatic assay, were further studied for a 
modulatory effect in a cell culture model by cell imaging. Based on the results 
from the screening obtained by the HDAC assay further analyses by image-
based screening and Western blot were performed to identify the possible 
mechanism of their action. 
HeLa cells were used for the image-based screening and Western blot analyses. 
 
D.9.1 Cell Imaging 
 
To study the modulating effects of natural substances on HDAC activity and on 
cell division process, the influence of small molecules was investigated in a cell 
model suitable for characterization the cytoskeletal phenotype after treatment 
with various compounds. 
Results 
 
 94 
A clear molecular and cell biological understanding of cytokinesis should result in 
the development of the new therapeutic strategies for treating a number of 
diseases, including cancer (Barr and Gruneberg, 2007). Based on the hypothesis 
that the failure of cell division results in the formation of genetically unstable cells 
which may go on to form malignant tumors, it was of interest to investigate the 
cell division process and which step in the cell division process is influenced by 
those natural compounds, which had inhibited HDAC activity in the enzyme 
assay. For this purpose HeLa cells were cultivated (C.10.2, page 38) and 
compounds of interest (aloin, capsaicin, rutin, sennoside A, sennoside B, 
stachydrine, verbascoside) were added to the medium at three concentrations 
(25, 37.5 and 50 µM). The incubation period was 24 and 48 hours. Fractions CR 
H2O, SPE F2, F3, and F4 from Leonuri herba were analyzed at concentrations of 
20, 30 and 40 µg/ml. DMSO was used as a control at a concentration of 0.1%. 
 
The fluorescence labelling for the actin cytoskeleton was performed with FICT-
conjugated phalloidin (green dye). The tubulin cytoskeleton in fixed cells was 
processed for tubulin immunofluorescence with TRITC-conjugated rhodamine 
(red dye). The nucleus was stained with DAPI (blue dye). The cell images are 
presented in the Figures 41-50, pages 95–103, respectively for 24 and 48 hours. 
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Figure 41. Influence of aloin on HeLa cell growth, cell cycle and cell division after 
cultivation of 24 (left) and 48 hours (right) 
50 µM   37.5 µM     50 µM  37.5 µM  
 
 
 
 
 
 
 
 
 
25 µM   control      25 µM  control 
 
After 24 hours aloin did show strong influence on cell growth and the mechanism 
of cell cycle in HeLa cells as compared with the control DMSO. After 48 hours of 
incubation the actin filaments were thickened and in the dividing cells the 
contraction ring was brighter. This fact indicated that aloin disturbed the cell 
cycle, although the mechanism of action is still unclear. 
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Figure 42. Influence of capsaicin on HeLa cell growth, cell cycle and cell division 
after of 24 (left) and 48 hours (right) 
50 µM   37.5 µM     50 µM  37.5 µM 
 
 
 
 
 
 
 
 
 
25 µM   control      25 µM  control 
 
Capsaicin at all concentrations strongly influenced the cell growth. The cell cycle 
mechanism was disturbed as showed at all concentrations after 24 and 48 hours 
as well. It was characteristic that the microfilaments changed their morphology, 
the tubulin bundles were very condensed and actin fibrils were loosening. 
Generally, after of 24 hours incubation the cells were in senescence and by 
further cultivation (48 hours) with capsaicin cell death was observed. 
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Figure 43. Influence of rutin on HeLa cell growth, cell cycle and cell division after 
24 (left) and 48 hours (right) 
50 µM   37.5 µM    50 µM  37.5 µM  
 
 
 
 
 
 
 
 
 
25 µM   control     25 µM  control 
 
Rutin at a concentration 50 µM affected the cell growth after 24 hours incubation, 
the HeLa cells continued to divide although the process was decelerated. At 
lower concentrations 25 and 37.5 µM the effect was as well observed but not that 
intense.  
After 48 hours incubation with rutin the cells showed elongated actin filaments. 
The tubulin was concentrated around the nuclei compared with the control 
DMSO. 
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Figure 44. Influence of sennosides A and B on HeLa cell growth, cell cycle and 
cell divison after 24 (left) and 48 hours (right) 
Sennoside A 
50 µM   37.5 µM     50 µM  37.5 µM 
 
 
 
 
 
 
 
 
 
25 µM   control      25 µM  control 
 
Sennoside B  
50 µM   37.5 µM     50 µM  37.5 µM 
 
 
 
 
 
 
 
 
 
25 µM   control      25 µM  control 
 
Due to the influence of sennosides A and B the tubulin microtubuli had changed 
their morphology, they were thicker and more condensed. The cell division after 
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24 and 48 hours incubation at all concentrations was disturbed im comparison 
with the control DMSO. 
 
Figure 45. Influence of stachydrine on HeLa cell growth, cell cycle and cell 
division after 24 (left) and 48 hours (right) 
50 µM   37.5 µM     50 µM  37.5 µM 
 
 
 
 
 
 
 
 
 
25 µM   control      25 µM  control 
 
Stachydrine at all concentrations strongly influenced the cell growth and the cell 
morphology. Substantially changes were observed in particular at a concentration 
of 50 µM after 24 and 48 hours cultivation. As expected the stachydrine induced 
apoptosis in the HeLa cells (Loh et al., 2009). 
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Figure 46. Influence of verbascoside on HeLa cell growth, cell cycle and cell 
division after 24 (left) and 48 hours (right) 
50 µM   37.5 µM     50 µM  37.5 µM 
 
  
 
 
 
 
 
 
 
25 µM   control      25 µM  control 
 
Verbascoside at all concentrations and incubation of either 24 or 48 hours 
strongly influenced the cell division. Typically the daughter cells were not fully 
separated, which was caused by incompletion of the last step of cell division 
(scission). The tubulin in all treated cells showed changed localization around the 
nucleus, was thicker and more condensed and led to accumulation of large 
multinuclear cells.  
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Figure 47. Influence of fraction CR H2O from Leonuri herba on HeLa cell growth, 
cell cycle and cell division after 24 (left) and 48 hours (right) 
40 µg/ml  30 µg/ml      40 µg/ml  30 µg/ml 
 
 
 
 
 
 
 
 
 
20 µg/ml  control      20 µg/ml  control 
 
The CR H2O extract at a concentration of 40 µg/ml after 24 hours strongly 
affected the cell growth.  
After 48 hours incubation at a concentration of 40 µg/ml large multinuclear cells 
were observed. It was clearly visible that the tubulin morphology and tubulin 
polymerization were disturbed as compared to the control. 
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Figure 48. Influence of fraction SPE F2 on HeLa cell growth, cell cycle and cell 
division after 24 (left) and 48 hours (right) 
40 µg/ml       30 µg/ml       40 µg/ml  30µg/ml 
 
 
 
 
 
 
 
 
 
20 µg/ml        control     20 µg/ml  control 
 
The influence of fraction SPE F2 at a concentration of 20 µg/ml after 24 and 48 
hours incubation was the strongest. Big multinuclear cells and as well many 
apoptotic cells were observed. The concentrations of 30 µg/ml and 40 µg/ml 
influenced the cell morphology as well the tubulin distribution around the nucleus, 
which was concentrated as compared to the control. 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
 103 
Figure 49. Influence of fraction SPE F3 on HeLa cell growth, cell cycle and cell 
division after 24 (left) and 48 hours (right) 
40 µg/ml       30 µg/ml     40 µg/ml     30 µg/ml 
 
 
 
 
 
 
 
 
 
20 µg/ml       control     20 µg/ml    control 
 
The influence of fraction SPE F3 at all concentrations and both incubation times 
was not strong. Cell growth and cell division were not disturbed as compared with 
the control DMSO.  
 
Figure 50. Influence of fraction SPE F4 on HeLa cell growth, cell cycle and cell 
division after 24 (left) and 48 hours (right) 
40 µg/ml       30 µg/ml     40 µg/ml     30 µg/ml 
 
 
 
 
 
 
 
 
 
20 µg/ml       control     20 µg/ml     control 
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Fraction SPE F4 at all concentrations strongly influenced the cell division similar 
to the effect caused by verbascoside and stachydrine. The daughter cells were 
not fully separated. F4 caused cell senescence at a concentration of 40 µg/ml 
and 48 hours incubation.  
 
The effects of the tested compounds, the fractions CR H2O, SPE F2 and F4 of 
Leonuri herba after incubation of 48h were more pronounced as compared with 
the influence after 24h incubation. The cell cycle was affected, the cell 
morphology was changed and the pattern of the actin and tubulin microfibrili was 
interfered by polymerization in tubulin bundles and untypical actin structures. 
Fraction CR H2O and the fractions SPE F2 and F4 after 48h had a massive effect 
on the cell division. The mechanism of action is still unknown. Further 
investigations are needed but could not be performed within the time frame of 
this thesis. 
 
D.9.2 Western Blot Analyses 
 
Western blot analyses of endogenous protein levels were performed using the 
nuclear extract to study the acetylated state of histones H3 (Figure 51, page 105) 
and H4 (Figure 52, page 106) and the whole cell lysate for characterization of 
expressed protein level of p21 (Figure 53, page 107) and acetylated tubulin 
(Figure 54, page 108). 
The Western blot experiments were used to study the influence on the acetylated 
state of histones (H3 and H4) and the tubulin by the modulators (sennosides A 
and B, lavandulifolioside, TSA and DMSO), which have shown some effect on 
HDAC activity.  
Protein p21 is a regulator of the cell fate which after stimulation leads to 
apoptosis. Thus, the activation of p21 was observed in HeLa cells after treatment 
with the selected compounds. The mechanism of action is unclear although it is 
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proved that altering the function, the regulation and the stability of HDACs 
influences strongly the cell fate. 
The experiments were done by cell stimulation with the tested compounds for 1, 
2, 4, 6, 8, 20 and 24 hours. Then, the cells were lysed and the amounts of 
acetylated H3 (histone 3), acetylated H4 (histone 4), acetylated tubulin and p21 
were characterized.  
Tubulin was used as a loading control (Figure 55, page 109). All experiments 
were carried out twice. 
 
Figure 51. Western blot analyses of the acetylated state of histone 3 (AcH3). 
Blank presents untreated HeLa cells compared to DMSO, TSA, lavandulifolioside 
(LA), sennosides A and B (SA and SB) treated HeLa cells 
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It was obvious that DMSO is a very active compound, which had a strong 
influence on the acetylated state of histone 3. After 6 hours treatment the level of 
acetylated histone was doubled and continued to increase rapidly. As expected, 
the influence of TSA was very strong. After achieving a maximum in hour 6, the 
level of acetylated histone 3 was almost constant up to the 24th hour. In the blank 
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control a slow increase up to the 6th hour in the acetylated state of histone 3 was 
observed, which then dropped as expected, when the cells underwent cell 
division. Sennosides A and B did not influence the protein expression of 
acetylated histone 3, whereas the lavandulifolioside showed a clear tendency to 
increase the acetylated state of histone 3 within 24 hours.  
 
Figure 52. Western blot analyses of the acetylated state of histone 4 (AcH4). 
Blank presents untreated HeLa cells compared to DMSO, TSA, lavandulifolioside 
(LA), sennosides A and B (SA and SB) treated HeLa cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparably to the acetylated state of histone 3, DMSO showed high potency on 
the expression level of the acetylated histone 4 after 6 hours of a treatment. The 
influence of TSA as well was strong. After achieving a maximum after 6 hours 
treatment the acetylated histone 4 level remained almost constant up to the 24th 
hour. The blank showed the same effect on the acetylated state of histone 4 as 
on the one of histone 3. The sennosides A and B remained without effect on the 
protein expression of acetylated histone 4, whereas the lavandulifolioside again 
showed a tendency to influence positively the acetylated state of histone 4.  
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Figure 53. Western blot analyses monitoring the expression of p21. Blank 
presents untreated HeLa cells compared to DMSO, TSA, sennosides A and B 
(SA and SB) treated HeLa cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The expression of p21 in HeLa cells, which were treated with DMSO, increased 
rapidly up to 4th hour, then dropped until 8th hour to the initial level and stayed 
constant to the hour 20. DMSO at the beginning of the treatment triggered the 
cells into apopotosis. The cells, which survived continued proliferating so that the 
expression level of p21 was constant.  
For TSA and sennoside B the expression level of p21 after the hour 8 was 
constant, whereas the level after treatment with sennoside A after 8 hours 
continued to increase as compared to the control.  
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Figure 54. Western blot analyses monitoring the acetylated state of tubulin. Blank 
presents untreated HeLa cells compared to DMSO, TSA, sennosides A and B 
(SA and SB) treated HeLa cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The acetylated tubulin level after treatement with DMSO, increased rapidly up to 
8th hour, and then stayed constant to the 20th hour. For TSA and sennoside B the 
expression level of acetylated tubulin after the hour 8 was constant, whereas the 
level of acetylated tubulin after treatment with sennoside A was higher until 4th 
hour and then continued to decrease as compared to the control.  
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Figure 55. Western blot analyses monitoring the tubulin level. Blank presents 
untreated HeLa cells compared to DMSO, TSA, sennosides A and B (SA and 
SB) treated HeLa cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The tubulin level was used as a loading control in for the Western blot analyses. 
The level of expressed tubulin was approximately the same in all samples, as 
expected.  
 
D.10 Sennosides A and B and their Influence on HDAC Activity 
and HeLa Cells Proliferation 
 
The sennosides A and B in vitro had shown a potential to modulate the HDAC 
activity at micromolar concentrations (D.2.1, page 55) and additional information 
about the mechanism of action on the acetylated state of tubulin was collected by 
cell imaging (page 98) and Western blot analyses (D.9.2, page 104). 
As well it was shown in another study (Tran et al., 2007) that the modulation in 
the tubulin acetylation induced changes in microtubules dynamics and altered the 
acetylated state of α-tubulin.  
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In order to clarify the mechanism of action of the sennosides A and B, they were 
tested with the recombinant enzymes HDAC 1, 2, 3 and 6 and the influence on 
the proliferation rate of HeLa cells was studied. 
 
D.10.1 Sennosides and HDAC Activity 
 
Preliminary measurements on HDAC inhibition had showed an IC50 value 180 µM 
for sennoside A, whereas the IC50 value of sennoside B was 220 µM using HeLa 
nuclear extract as HDAC source. To test the activity of these compounds more 
detailed, measurements were performed using HDAC1, 2 and 3 recombinant 
enzymes in vitro. The effect of sennoside A was strong. At a concentration of 50 
µM it showed an inhibition of 40% of the enzyme activity of HDAC3. It did not 
affect the activity of HDAC1 and HDAC2 at the tested concentration. Sennoside 
B at a concentration of 50 µM did not modulate the activity of any of the 
recombinant enzymes.  
As the cell imaging data had shown that the sennosides affect the structure of 
tubulin, the influence of the sennosides on the HDAC6 activity was studied as 
well. HDAC6 is predominantly located in cytoplasma and has the potential to 
deacetylate tubulin and microtubules (Zhang et al., 2003, Tran et al., 2007) and 
influences on HDAC6 activity alter the cell migration (Tran et al., 2007). 
 
The measurement in the HDAC assay showed no effect of sennoside B on the 
activity of HDAC6, whereas sennoside A was inhibiting HDAC6 with an IC50 of 95 
µM (Figure 56, page 111). 
 
 
 
 
 
 
Results 
 
 111 
Figure 56. Influence of sennoside A on the HDAC6 activity (statistics: one-way 
ANOVA, no significant difference) 
 
 
 
 
 
 
 
 
 
 
         
 
 
 
Although the performed analyses (HDAC assay and cell imaging) showed strong 
influence of sennoside A on the activity of HDAC3, HDAC6 and acetylated 
tubulin, the mechanism of its action is still unclear. 
 
D.10.2 Sennosides and HeLa Cells Proliferation 
 
In order to study the effect of the sennosides A and B on the proliferation rate of 
HeLa cells, a crystal violet staining was carried out. As demonstrated in Figure 57, 
page 112, HeLa cells treated with sennoside A and B at three different 
concentrations (1, 10 and 100 µM) for 48 hours were not affected as determined 
by cell counting. A similar result was obtained by treating the cells for 72 hours 
with sennoside B and performing the crystal violet assay (Figure 58, page 112). 
However, after treatment with sennoside A for 72 hours the cell proliferation was 
affected in a concentration dependent manner (1 to 100 µM). 
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Figure 57. Influence of different concentrations of sennosides A and B (1, 10 and 
100 µM) on the proliferation of HeLa cells after 48h incubation measured by 
crystal violet assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58. Influence of different concentrations of sennosides A and B (1, 10 and 
100 µM) on the proliferation of HeLa cells after 72h incubation measured by 
crystal violet assay 
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These results were confirmed by use of the resazurin assay. The inhibition of the 
proliferation rate of HeLa cells by sennoside A occurred after 72 hours in a 
concentration dependent manner. 
 
D.11 Immunoprecipitation (IP) of HDAC5 
 
HDAC5 belongs to class II HDAC enzymes and is responsible the cardiac 
development and growth through different pathways. The suppression of the 
hypertrophic growth of cardiomyocytes by HDAC5 was investigated in a mouse 
model (Chang et al., 2005). Due to its implementation in the regulation of cardiac 
myocytes HDAC5 was of interest for our study and should be isolated by 
immunoprecipitation. 
An immunoprecipitation study was performed to explore the content ofHDAC5 in 
the VSMC nuclear extract and as well as to obtain pure native HDAC5 enzyme, 
for the further characterization of the enzyme kinetics. For this aim A-Sepharose 
beads, an HDAC5 antibody and VSMC nuclear extract were used (see C. 8 page 
35). The results are presented in Figure 59. 
 
Figure 59. HDAC activity of the VSMC nuclear extract and products from 
immunoprecipitation 
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The activity of VSMC nuclear extract was assumed as 100 % and compared to 
the activity of all IP products. The supernatant obtained after centrifugation of the 
A-Sepharose beads after addition of 100 µl lysis buffer was named SN1. SN2 
was obtained after the second treatment of the A-Sepharose beads with lysis 
buffer. Immunoprecipitaion product 1 (IP1) was designated as first pellet product 
between the HDAC5 from the VSMC nuclear extract and the A-sepharose beads, 
whereas with IP2 was indicated the second pellet product after the second 
centrifugation step. As expected IP1 and IP2 did not show any significant activity 
(10.5% and 7.5%, respectively), in contrary, SN1 possessed 65% higher activity 
than the VSMC nuclear extract. 
 
Further, IP products were analyzed by gel electrophoresis. Commassie staining 
and Western blot were performed in order to determine a presence of HDAC 5 in 
the nuclear extract and IP products, Figure 60. 
 
Figure 60. Analysis of the VSMC nuclear extracts and the IP products by 
Commassie staining (left blot) and Western blot (right blot) 
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1 protein marker (Biorad, 20 - 250 kDa). 2 mixture of VSMC nuclear extract, anti-
HDAC5 and A-sepharose beads, 3 SN1, 4 SN2 and 5 VSMC nuclear extract. 
 
The molecular weight of the pure HDAC5 is around 120 kDa. In the Commassie 
staining blot 2 revealed an intense blue zone with a molecular weight of around 
120 kDa and proved that the HDAC5 enzyme was completely bound on the A-
sepharose beads with HDAC5 antibody. A small amount was detected in SN1 
product as well. Thus, the method can be used for the enrichment and the 
purifiction of HDAC5 enzyme. 
 
In conclusion, it was possible by IP procedure to achieve a high concentration of 
the HDAC5 (comparison between band 2 and 5 in the Commassie staining blot). 
The disadvantage of the IP procedure was that the enzyme was obtained in a 
diluted solution and instable.  
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E Discussion 
 
E.1 An in vitro Assay on HDAC Modulation and its Application 
for Bioactivity-Guided Fractionation 
 
Protein acetylation and deacetylation are major intracellular modification systems 
and important factors contributing to the regulation of the cell fate.  
 
The treatment of diseases can be implemented at various levels of signaling 
pathways. It is essential for targeted drug discovery to understand the overall 
pathways and to have adeguate assay and cell based models in which these 
pathways can be studied and dissected. Validated assay- and cell-systems are 
indispensable in preliminary screening.  
 
The methods and the models applied in this study aimed on the screening of 
plant extracts, fractions and natural compounds for HDAC modulation. The 
enzymatic HDAC assay represents a model for fast answers in the search for 
modulators of HDAC activity. A fluorimetric enzyme assay was validated to 
investigate HDAC inhibition by different natural compounds in nuclear extracts of 
HUVECs, VSMCs and HeLa cells. The investigation involved screening of 
numerous natural products. 
 
This work presents for the first time the application of a fluorimetric assay for the 
investigation of HDAC modulators in complex extracts from plant origin. A fast 
enzymatic method for the determination of HDAC activity and the identification of 
potent natural product-based inhibitors of HDAC activity was established. 
 
The optimized test system combines high sensitivity, speed and reproducibility 
for the investigation of plant extracts of medium to high polarity. Our modified 
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HDAC assay is well suited for medium to HTS efforts in the screening of plant 
extracts, fractions and natural compounds for HDAC modulators.  
 
Cultivation of HeLa cells was the most frequently used for the preparation of the 
HDAC source. The cells rapidly produced large quantities of biomass. The 
quality, yield and composition of the HDAC source were very homogeneous and 
constant in all nuclear extracts prepared for the experiments.  
 
Due to use of total nuclear extracts of HeLa cells the assay is not completely 
specific to study the effects on the enzyme activity of class I and class II HDAC 
family. Uncharacterized cofactors are present in the total nuclear extract, which 
can contribute to lysine hydrolysis and/ or affect the properties of the test 
compounds. Nevertheless, this system mimics the natural environment of the 
enzyme and assures its activity and stability.  
 
An ε-acetylated lysine-based substrate C-terminally coupled with 4-methyl-
coumarine-7-amide (MCA) was synthesized by the group of PhD Mazitchek, 
General Hospital of Massachusetts, Boston, US. The binding affinity of the MCA 
was investigated in detail. As the HeLa nuclear extract contains both class I and 
II HDACs, the binding affinity of the substrate was determined for the 
recombinant enzymes HDAC3 and HDAC6. KdHDAC3 was 2 ± 0.2 and KdHDAC6 4.6 
± 0.2 nM, respectively. This substrate is suitable for screenings, in which an 
incubation time of minimum 60 minutes is important for complete turnover 
(Mazitchek et al., 2008). Other studies have shown that many factors affect the 
specificity of the enzyme and substrate. A site specificity is dependent on the 
presence of cofactors and the nature of acetyl group, cleaved from the substrate. 
Furthermore, additional substrate phosphorylation or influence of corepressor 
binding on the enzyme activity leads to strong influence of the deacetylation 
(Riester et al., 2004, 2007, Bradner et al. 2010).  
Our study confirmed that the used substrate is suitable for screening in the 
search of HDAC modulators with HeLa nuclear extract. Additionally, experiments 
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were performed with the recombinant HDAC1, 2, 3 and 6 and nuclear extracts 
from HeLa, HUVEC, VSMC, MCF7 and HL-60 cells (not all results are shown) 
and have also shown the suitability of this substrate. 
 
Individual recombinant purified enzymes and acetylated histones should be used 
instead of nuclear extract and MCA-coupled peptide for more detailed 
mechanistic studies in the search of selective HDAC inhibitors. 
 
A further advantage of the assay is the use of small reaction volumes, which 
makes it a very cost effective method. The consumption of reagents and analytes 
is very little. 
 
E.2 Effect of Extracts of Leonuri herba on HDAC Activity 
 
In a first pilot experiment with an extract of Leonuri herba the applicability of the 
assay for the bioactivity-guided fractionation of complex extracts was 
successfully demonstrated. 
 
However, special caution has to be taken when working with highly 
autofluorescent, lipophilic or tannin rich extracts.  
 
Our work has shown that coumarins and similar derivatives strongly interfere with 
the measurements due to autofluorescence. In the examination of extracts or 
fractions presumably containing such compounds a general check for blue 
fluorescent bands by TLC is highly recommended.  
 
Extracts containing tannins may lead to precipitation of the proteins in the assay 
and to false positive results. Thus, detannification is indispensable before tests 
on HDAC activity. 
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For very apolar extracts and fractions other assays have to be used due to 
insufficient solubility of such mixtures in DMSO and reaction buffer. 
 
To sum up, the presented results proved the applicability of a fluorimetric assay 
for a rapid and effective primary screening of complex extracts and fractions from 
plant origin. It is a well-suited tool for such an approach. 
 
E.3 Effect of Sennosides on HDAC Activity 
 
Information about the inhibitory potency of the dianthrones, sennosides A and B 
on HDAC activity was not available. Our results showed that sennoside A inhibits 
HeLa nuclear extract possibly by interfering with HDAC6. In this study we 
determined the IC50 of 95 µM sennoside A for HDAC6. 
In the used cell system sennoside A led to interaction with tubulin and in a 
concentration dependent manner decreased the proliferation rate of HeLa cells. 
However, the mechanism of inhibition by sennoside A is still unclear. 
 
Nevertheless, despite the advantages of different culture models, it is clear that in 
vivo studies and species extrapolation is necessary. 
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F Conclusion Remarks 
 
 
HDACs are involved in regulation of diverse cellular processes by altering the 
protein structure and function and by influencing the cell fate by modulation of 
nonhistone proteins and transcriptional factors.  
 
The ability of HDAC inhibitors to modulate transcriptional activity and to alter 
various cellular functions, such as cell differentiation, cell cycle progression, 
apoptosis, cytoskeletal modifications and angiogenesis, built by HDAC research 
as a very important field. By targeting these key components of tumor 
proliferation, HDACi will play an important role as anti-cancer drugs. A major 
reason for their key role in the oncology is that they are able to improve the 
efficacy of already existing agents. The synergisms of HDACi with classic 
chemotherapeutic agents and angiogenesis inhibitors have shown positive 
influence on the treatments. This mechanism is still under investigation 
(Emanuele et al., 2008).  
 
The efficacy of HDACi depends on the degree of suppression of cancer cell 
proliferation, survival, migration, invasion, metastasis and angiogenesis by 
modulation of the gene regulation in cancer cells. HDACs regulate these 
processes by single and multicomplex pathways in complex mechanism of 
actions, which are not elucidated yet (Mottet and Castronovo, 2008). 
A hypothesis that HDAC inhibitors could be beneficial in multiple cancers and be 
applicable alongside a broad range of therapeutics is still a target.  
 
Over the past few years, some HDAC inhibitors have entered the clinical studies. 
For example, HDAC inhibitors of the group of hydroxymates are used in phase I 
(PCI24781, LAQ824, SB939 and JNJ-16241199), phase II (panobinostat, 
belinostat and ITF2357) and phase III (SAHA) clinical trials. The group of short 
chain fatty acids (butyrate and valproate), cyclic tetrapeptides (depsopeptide) and 
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the benzamides (MS-275, MGCD0130 and N-acetyldinaline) are already in phase 
II clinical trials (Emanuele et al., 2008, Takai and Narahara, 2010). The HDACi 
FK228 is already used for the treatment of peripheral T-cell lymphoma, 
cutaneous T-cell lymphoma, chronic lymphocytic leukemia and androgen 
independent prostate cancer. SAHA, an orally bioavailabile HDACi, is 
implemented against solid tumors, leukemia and lymphomas (Marks and 
Breslow, 2007).  
 
Adverse cardiologic and hematological effects of first generation inhibitors are 
observed and the need for new candidates, selective inhibitors with higher 
efficacy and safety is still a challenge in this research field. 
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G Future Approach 
 
 
Future research is expected to lead to a better understanding of the molecular 
targets of HDACs and to facilitate the development of more potent and specific 
inhibitors of these enzymes. Selective inhibitors of the HDACs are currently 
lacking and the mechanism of action is still unknown. The aim can be the 
discovery of small molecules that specifically inhibit proteins in the HDAC 
pathway. Optimization and characterization could turn the small molecules into 
potential anti-cancer drugs. Using specific inhibitors in cancer model systems will 
bring better understanding of how HDAC modulations contribute to tumor 
development and progression. 
 
In broader terms, the assay can be modified and used to find inhibitors of virtually 
signaling pathways where HDACs are involved. This could be a useful approach 
to study the role of HDAC in the regulation of gene expression and to target other 
biological pathways involved in cancer. 
 
A further challenge is to learn the nature of the combinatorial HDAC-protein-DNA 
interaction and to understand how these interactions vary in different cell types 
and tissues, in order to target a specific region of the body by disease treatment. 
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I Appendix 
 
 
I.1 Abbreviations 
 
Ac - acetylation 
ADP - adenosine diphosphate  
AMC - 7-amino 4-methylcoumarin 
appr. – approximately 
APS – ammonium persulphate 
Ara – arabinose 
ATP - adenosine triphosphate 
b.w. - body weight 
C-source - carbon source 
CA - caffeic acid 
CB – cytoskeletal buffer 
CBS – cytoskeletal buffer with 1M saccharose 
CNS - central nervous system 
CClA – chlorogenic acid 
CVD – cardiovascular disease 
DMEM - Dulbecco’s modified Eagle medium 
DMSO - dimethyl sulfoxide 
DNA - deoxyribonucleic acid 
DTT - 1-4 dithiothreitol 
ECL – enhanced chemiluminescence 
EDTA - ethylenediaminetetraacetic acid 
EGTA - ethylenglycol-bis(2-aminoethyl)-N,N,N’,N’-tetraacetic acid 
EtOAc - ethyl acetate 
EtOH - ethanol 
FOXO - forkhead box O, transcription factor 
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Glu - glucose 
H1, H2A, H2B, H3, H4 - histones 
HAT - histone acetyltransferase  
HDAC - histone deacetylase 
HDACi - histone deacetylase inhibitor 
HDACm - histone deacetylase modulator 
HeLa - cervical cancer cells from Henrietta Lacks 
HEPES - 4-(2-hydroxyethyl)piperazine-1-ethansulfonic acid  
Hyp - hyperoside 
HUVECs - human umbilical vein endothelial cells 
HTS – high-throughput screening 
IC50 - the half maximum inhibitory concentration 
K – lysine 
LA - lavandulifolioside 
Lc - Leonurus cardiaca L. 
MCA – substrate C-terminally coupled with 4-methyl-coumarine-7-amide 
MeOH - methanol  
MES – 2-(N-morpholino)ethanesulfonic acid 
MgCl2 - magnesium dichloride 
NAD - nicotinamide adenine dinucleotide 
NF-kB - nuclear factor kappa-light-chain-enhancer of activated B-cells 
PAA – polyacrylamide 
PAGE - polyacrylamide gel electrophoresis 
p21 – cell cycle regulatory protein 21 
p53 - tumor suppressor protein 53 
PBS - phosphate buffered saline 
PMSF - phenylmethylsulfonylfluoride 
PTMs - posttranslational modifications 
R2 - linear correlation factor 
RA – rosmarinic acid 
Rha - rhamnose 
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RFU - relative fluorescence units 
rpm - rotations per minute 
RR - Ratanhiae radix Domb. Burd ET Simp. 
RT - room temperature 
RV - reservoir volume 
SA - sennoside A 
SB - sennoside B 
SCC – Sephadex LH-20 column chromatography 
SDS – sodium dodecyl sulphate 
SIRT - sirtuin 
SPE - solid phase extraction 
TCM - traditional Chinese medicine 
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TSA - trichostatin A 
TX – triton X-100 
VS - verbascoside 
VSMCs - vascular smooth muscle cells 
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Abstract 
 
Cardiovascular diseases (CVD) today are the one of the leading causes of death. 
Recent studies suggest a key role of histone deacetylases (HDACs) in the 
control of pathological cardiac remodeling. Thus, the main focus of our study was 
to investigate the effect of natural products on HDAC activity.  
For the bioactivity-guided screening for HDAC modulators from plant sources a 
fluorimetric assay was extensively validated and applied for the first time to 
complex extracts and fractions.  
Leonuri herba, a drug used in European traditional medicine against cardiac 
complaints, served as an example for a bioactivity-guided approach. Extracts of 
different polarity were tested in the established assay and fractionated by 
different chromatographic methods under consideration of their HDAC inhibiting 
activity. Lavandulifolioside was isolated as active compound and its structure 
established by various spectrometric/spectroscopic methods. Although for the 
substance an IC50 value in the micromolar range (220µM) was determined only, 
this study showed impressively that the established assay is an adequate tool in 
the bioactivity-guided search for HDAC modulators in plant extracts, as the 
system combines high sensitivity, speed and effectiveness. 
For some active plant secondary metabolites e.g. sennoside A the underlying 
molecular mechanism were studied in more detail. Although the mechanism 
remained unclear and further investigations on the molecular mechanism of 
action are needed, these findings increased the understanding of interactions 
between HDACs and some natural products. 
Abstrakt 
 
Herz-Kreislauf-Erkrankungen (CVD) stellen heute die führende Todesursache 
dar. Neuere Studien zeigen dass, Histonedeacetylasen (HDACs) eine Schlüssel-
rolle bei der Steuerung pathologischer Prozesse des Herzens spielen dürften.  
Der Schwerpunkt der vorliegenden Arbeit war daher die Wirkung von Natur-
stoffen auf die HDAC-Aktivität. 
Für das aktivitäts-geleitete Screening nach HDAC-Modulatoren pflanzlicher Her-
kunft wurde ein fluorimetrischer Assay umfangreich validiert und erstmalig an 
komplexe Extrakte und Fraktionen angewendet.  
Leonuri herba, eine Arzneidroge der traditionellen europäischen Medizin gegen 
Herzbeschwerden, diente als Beispiel für einen aktivitätsgeleiteten Untersu-
chungsansatz. Extrakte unterschiedlicher Polarität wurden mit dem etablierten 
Assay getestet und mittels unterschiedlicher chromatographischer Techniken 
unter Berücksichtigung ihrer HDAC-hemmenden Wirkungen fraktioniert. Lavan-
dulifolioside konnte als aktive Substanz isoliert werden und die Strukutklärung 
erfolgte mittels verschiedener spektrometrischer/spektroskopischer Methoden. 
Obwohl für die Substanz nur ein IC50 Wert im mikromolaren Bereich (220µM) 
bestimmt wurde, zeigte die Untersuchung eindrucksvoll, dass der etablierte 
Assay eine geeignete Methode für die aktivitäts-geleitete Suche nach HDAC 
Modulatoren in Pflanzenextrakten darstellt und entsprechende Empfindlichkeit 
mit schnellen Analysen und überzeugender Effektivität kombiniert.  
Für einige aktive pflanzliche Sekundärmetaboliten z.B. Sennoside A wurden 
auch zugrundeliegende molekulare Mechanismen detaillierter untersucht. 
Obwohl die Mechanismen nicht geklärt werden konnten und weitere Studien 
hinsichtlich der molekularen Wirkungsmechanismen erforderlich sind, tragen die 
Ergebnisse zu einem besseren Verständnis der Wechselwirkungen zwischen 
HDACs und den untersuchten Naturstoffen bei.  
 
 
